HealthLynked (HLYK) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 15, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Information [Line Items]
Entity Registrant Name	HealthLynked Corp.
Entity Central Index Key	0001680139
Entity File Number	000-55768
Entity Tax Identification Number	47-1634127
Entity Incorporation, State or Country Code	NV
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	1265 Creekside Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	Naples
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34108
Entity Phone Fax Numbers [Line Items]
City Area Code	(800)
Local Phone Number	928-7144
Entity Listings [Line Items]
Title of 12(b) Security	None
No Trading Symbol Flag	true
Entity Common Stock, Shares Outstanding		281,942,151

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash	$ 23,491	$ 247,222
Accounts receivable, net of allowance for doubtful accounts of $-0- and $-0- as of March 31, 2024 and December 31, 2023, respectively	33,620	20,861
Inventory, net	136,205	133,222
Prepaid expenses and other current assets	40,016	55,210
Contingent sale consideration receivable, current portion	1,663,163	199,645
Total Current Assets	1,896,495	656,160
Property and equipment, net of accumulated depreciation of $550,531 and $521,062 as of March 31, 2024 and December 31, 2023, respectively	263,884	290,755
Intangible assets, net of accumulated amortization of $315,730 and $258,690 as of March 31, 2024 and December 31, 2023, respectively	826,808	883,848
Right of use lease assets	853,525	935,812
Deposits, long term portion	50,047	50,047
Contingent sale consideration receivable, long term portion		1,463,518
Total Assets	3,890,759	4,280,140
Current Liabilities
Accounts payable, accrued expenses and other current liabilities	705,124	614,178
Contract liabilities	331,440	271,774
Lease liability, current portion	332,692	326,033
Notes payable, current portion, net of unamortized original issue discount of $104,288 and $166,487 as of March 31, 2024 and December 31, 2023, respectively	462,847	584,323
Indemnification liability	143,974	143,974
Total Current Liabilities	2,694,719	2,412,024
Long-Term Liabilities
Lease liability, long-term portion	524,546	613,386
Government notes payable, long-term portion	450,000	450,000
Total Liabilities	3,669,265	3,475,410
Commitments and contingencies (Note 14)
Shareholders’ Equity
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 281,064,958 and 275,964,958 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	28,107	27,597
Series B convertible preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 2,750,000 and 2,750,000 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	2,750	2,750
Common stock issuable, $0.0001 par value; 1,055,536 and 2,764,352 as of March 31, 2024 and December 31, 2023, respectively	54,570	281,682
Additional paid-in capital	43,556,921	42,525,837
Accumulated deficit	(43,420,854)	(42,033,136)
Total Shareholders’ Equity	221,494	804,730
Total Liabilities and Shareholders’ Equity	3,890,759	4,280,140
Related party
Current Liabilities
Notes payable and other amounts due to related party, net of unamortized original issue discount of $281,579 and $34,834 as of March 31, 2024 and December 31, 2023, respectively	$ 718,642	$ 471,742

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Accounts receivable, net of allowance for doubtful accounts (in Dollars)	$ 0	$ 0
Property, plant and equipment, net of accumulated depreciation (in Dollars)	550,531	521,062
Intangible assets, net of accumulated amortization (in Dollars)	315,730	258,690
net of unamortized original issue discount (in Dollars)	$ 104,288	$ 166,487
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	281,064,958	275,964,958
Common stock, shares outstanding	281,064,958	275,964,958
Common stock issuable, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock issuable, shares	1,055,536	2,764,352
Related party
net of unamortized original issue discount (in Dollars)	$ 281,579	$ 34,834
Series B convertible preferred stock
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	2,750,000	2,750,000
Preferred stock, shares outstanding	2,750,000	2,750,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue
Total revenue	$ 1,004,232	$ 1,755,154
Operating Expenses and Costs
Practice salaries and benefits	583,156	963,657
Other practice operating expenses	482,583	624,247
Cost of product revenue	30,579	32,060
Selling, general and administrative expenses	999,443	1,103,748
Depreciation and amortization	86,509	88,077
Total Operating Expenses and Costs	2,182,270	2,811,789
Loss from operations	(1,178,038)	(1,056,635)
Other Income (Expenses)
Loss on extinguishment of debt	(96,660)	(44,763)
Amortization of original issue discounts on notes payable	(108,265)	(63,360)
Change in fair value of contingent acquisition consideration	76	(1,706)
Interest expense and other	(4,831)	(11,381)
Total other income (expenses)	(209,680)	(121,210)
Loss from continuing operations before provision for income taxes	(1,387,718)	(1,177,845)
Provision for income taxes
Loss from continuing operations	(1,387,718)	(1,177,845)
Discontinued operations (Note 4)
Loss from operations of discontinued operations		(44,289)
Gain from disposal of discontinued operations		2,674,069
Gain on discontinued operations		2,629,780
Net income (loss)	$ (1,387,718)	$ 1,451,935
Loss per share from continuing operations, basic and diluted:
Basic (in Dollars per share)	$ 0	$ 0
Fully diluted (in Dollars per share)	0	0
Gain (loss) on discontinued operations, basic and diluted:
Basic (in Dollars per share)	0	0.01
Fully diluted (in Dollars per share)	0	0.01
Net loss per share, basic and diluted:
Basic (in Dollars per share)	0	0.01
Fully diluted (in Dollars per share)	$ 0	$ 0.01
Weighted average number of common shares:
Basic (in Shares)	280,484,268	257,131,222
Fully diluted (in Shares)	280,484,268	257,131,222
Patient service revenue, net
Revenue
Total revenue	$ 963,621	$ 1,700,281
Subscription and event revenue
Revenue
Total revenue	7,628	16,299
Product revenue
Revenue
Total revenue	$ 32,983	$ 38,574

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Shareholders’ Equity (Unaudited) - USD ($)	Common Stock	Preferred Stock	Common Stock Issuable	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2022	$ 25,594	$ 2,750	$ 225,584	$ 41,081,455	$ (41,020,933)	$ 314,450
Balance (in Shares) at Dec. 31, 2022	255,940,389	2,750,000
Sales of common stock pursuant to Standby Equity Purchase Agreement	$ 22			18,743		18,765
Sales of common stock pursuant to Standby Equity Purchase Agreement (in Shares)	225,000
Other sales of common stock	$ 200			125,998		126,198
Other sales of common stock (in Shares)	2,000,000
Fair value of warrants allocated to proceeds of common stock				73,802		73,802
Fair value of warrants allocated to proceeds of related party debt				95,393		95,393
Consultant and director fees payable with common shares and warrants			54,972			54,972
Shares and options issued to employees	$ 99		(34,200)	67,229		33,128
Shares and options issued to employees (in Shares)	987,500
Net Income (loss)					1,451,935	1,451,935
Balance at Mar. 31, 2023	$ 25,915	$ 2,750	246,356	41,462,620	(39,568,998)	2,168,643
Balance (in Shares) at Mar. 31, 2023	259,152,889	2,750,000
Balance at Dec. 31, 2023	$ 27,597	$ 2,750	281,682	42,525,837	(42,033,136)	804,730
Balance (in Shares) at Dec. 31, 2023	275,964,958	2,750,000
Sales of common stock pursuant to Standby Equity Purchase Agreement	$ 510			255,413		255,923
Sales of common stock pursuant to Standby Equity Purchase Agreement (in Shares)	5,100,000
Fair value of warrants allocated to proceeds of common stock				99,077		99,077
Fair value of warrants allocated to proceeds of related party debt				209,943		209,943
Fair value of beneficial conversion feature allocated to proceeds of related party debt				146,405		146,405
Consultant and director fees payable with common shares and warrants			43,437			43,437
Shares and options issued to employees			(270,549)	320,246		49,697
Net Income (loss)					(1,387,718)	(1,387,718)
Balance at Mar. 31, 2024	$ 28,107	$ 2,750	$ 54,570	$ 43,556,921	$ (43,420,854)	$ 221,494
Balance (in Shares) at Mar. 31, 2024	281,064,958	2,750,000

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Flows from Operating Activities
Net income (loss)	$ (1,387,718)	$ 1,451,935
Loss from discontinued operations		44,289
Adjustments to reconcile net loss to net cash used in operating activities:
Gain from disposal of discontinued operations		(2,674,069)
Depreciation and amortization	86,509	88,077
Stock based compensation, including amortization of deferred equity compensation	93,133	88,101
Amortization of debt discount	108,265	63,360
Loss on extinguishment of debt	96,660	44,763
Change in fair value of contingent acquisition consideration	(76)	1,706
Changes in operating assets and liabilities:
Accounts receivable	(12,760)	811
Inventory	(2,983)	(97)
Prepaid expenses and other current assets	15,194	56,566
Right of use lease assets	82,287	334,157
Accounts payable and accrued expenses	89,149	(219,064)
Lease liability	(82,181)	(333,881)
Contract liabilities	59,666	996
Net cash used in continuing operating activities	(854,855)	(1,052,350)
Net cash used in discontinued operating activities	0	(47,163)
Net cash used in operating activities	(854,855)	(1,099,513)
Cash Flows from Investing Activities
Proceeds from sale of discontinued operations		781,381
Acquisition of property and equipment	(2,598)
Net cash provided by (used in) continuing investing activities	(2,598)	781,381
Net cash used in discontinued investing activities
Net cash provided by (used in) investing activities	(2,598)	781,381
Cash Flows from Financing Activities
Proceeds from sale of common stock	355,000	200,000
Proceeds from related party notes payable	500,000	455,000
Proceeds from third party notes payable		100,000
Repayment of related party notes payable	(37,602)	(229,500)
Repayment of third party notes payable	(183,676)	(200,593)
Net cash provided by continuing financing activities	633,722	324,907
Net cash provided by discontinued financing activities
Net cash provided by financing activities	633,722	324,907
Net increase (decrease) in cash	(223,731)	6,775
Cash, beginning of period	247,222	61,891
Cash, end of period	23,491	68,666
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	6,579	3,272
Cash paid during the period for income tax
Schedule of non-cash investing and financing activities:
Common stock issuable issued during period		34,105
Fair value of options issued in satisfaction of common stock issuable	270,549
Fair value of warrants allocated to proceeds of related party notes payable	209,943	95,393
Fair value of beneficial conversion feature allocated to proceeds of related party notes payable	146,405
Net carrying value of equity liabilities (assets) written off		2,350
Proceeds from sale of common stock under Standby Equity Purchase Agreement applied to note payable balance		$ 18,743
Incremental fair value of convertible note payable to related party resulting from refinancing	33,121
Note payable to related party balance classified as accrued interest	$ 1,875

Business and Business Presentat

Business and Business Presentation	3 Months Ended
	Mar. 31, 2024
Business and Business Presentation [Abstract]
BUSINESS AND BUSINESS PRESENTATION	NOTE 1 – BUSINESS AND BUSINESS PRESENTATION HealthLynked Corp. (the “Company”) was incorporated in the State of Nevada on August 4, 2014. On September 2, 2014, the Company filed Amended and Restated Articles of Incorporation with the Secretary of State of Nevada setting the total number of authorized shares at 250,000,000 shares, which included up to 230,000,000 shares of common stock and 20,000,000 shares of “blank check” preferred stock. On February 5, 2018, the Company filed an Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of Nevada to increase the number of authorized shares of common stock to 500,000,000 shares. The Company currently operates in three distinct divisions: the Health Services Division, the Digital Healthcare Division, and the Medical Distribution Division. The Health Services Division is comprised of the operations of (i) Naples Women’s Center (“NWC”), a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology) and General Practice, (ii) Naples Center for Functional Medicine (“NCFM”), a Functional Medical Practice engaged in improving the health of its patients through individualized and integrative health care, (iii) Bridging the Gap Physical Therapy (“BTG”), a physical therapy practice in Bonita Springs, Florida that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery, and (iv) Aesthetic Enhancements Unlimited (“AEU”), a patient service facility specializing in minimally and non-invasive cosmetic services acquired by the Company in May 2022. The Digital Healthcare Division develops and operates an online personal medical information and record archive system, the “HealthLynked Network,” which enables patients and doctors to keep track of medical information via the Internet in a cloud-based system. The Medical Distribution Division is comprised of the operations of MedOffice Direct LLC (“MOD”), a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States. During October 2022, the Company’s Board of Directors (the “Board”) approved a plan to sell the Company’s ACO/MSO (Accountable Care Organization / Managed Service Organization) Division, comprised of the operations of Cura Health Management LLC (“CHM”) and its subsidiary ACO Health Partners LLC (“AHP”), which operates an Accountable Care Organization (“ACO”) and Managed Service Organization (“MSO”) that assists physician practices in providing coordinated and more efficient care to patients via the Medicare Shared Savings Program (“MSSP”) as administered by the Centers for Medicare and Medicaid Services (the “CMS”). On January 17, 2023, the Company entered into an Agreement and Plan of Merger (the “AHP Merger Agreement”) pursuant to which PBACO Holding, LLC, an operator of ACOs, (“Buyer”) agreed to buy, and the Company agreed to sell, AHP. See Note 4, “Discontinued Operations,” for additional information. These unaudited condensed consolidated financial statements reflect all adjustments including normal recurring adjustments, which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America (“GAAP”). These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the years ended December 31, 2023 and 2022, respectively, which are included in the Company’s Form 10-K, filed with the United States Securities and Exchange Commission (the “Commission”) on April 1, 2024. The Company assumes that the users of the interim financial information herein have read, or have access to, the audited consolidated financial statements for the preceding period, and that the adequacy of additional disclosure needed for a fair presentation may be determined in that context. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of results for the entire year ending December 31, 2024. On a consolidated basis, the Company’s operations are comprised of the parent company, HealthLynked Corp., and its five subsidiaries: NWC, NCFM, BTG, MOD and AEU. Results through January 17, 2023 also include operations of AHP, which was sold, and CHM, which was discontinued, both effective as of January 17, 2023. All significant intercompany transactions and balances have been eliminated upon consolidation. In addition, certain amounts in the prior periods’ consolidated financial statements have been reclassified to conform to the current period presentation. Uncertainty Due to Geopolitical Events Due to the Hamas-Israel and Russia-Ukraine conflicts, there has been uncertainty and disruption in the global economy. Although these events did not have a direct material adverse impact on the Company’s financial results for the three months ended March 31, 2024, at this time the Company is unable to fully assess the aggregate impact the Hamas-Israel and Russia-Ukraine conflicts will have on its business due to various uncertainties, which include, but are not limited to, the duration of the conflicts, the conflicts’ effect on the economy, the impact on the Company’s businesses and actions that may be taken by governmental authorities related to the conflicts.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Business and Business Presentation [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the presentation of the accompanying condensed consolidated financial statements follows: Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP. All amounts referred to in the notes to the condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about fair valuation of acquired intangible assets; cash flow and fair value assumptions associated with measurements of contingent sale consideration receivable, contingent acquisition consideration payable, and impairment of intangible assets; valuation of inventory; collection of accounts receivable; the valuation and recognition of stock-based compensation expense; valuation allowance for deferred tax assets; and borrowing rate consideration for right-of-use (“ROU”) lease assets including related lease liability and useful life of fixed assets. Revenue Recognition Patient service revenue Patient service revenue is earned for patient services provided to patients at our NWC facility, functional medicine services provided to patients at our NCFM facility, and physical therapy services provided to patients at our BTG facility. Patient service revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients and third-party payors (including health insurers and government programs) and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Company bills patients and third-party payors within days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time includes revenue from NCFM annual access contracts (called the Medical Membership and Concierge Program prior to October 1, 2023 and Optimal Health 365 Access Plan thereafter), NWC annual administration fees, and BTG physical therapy bundles. Revenue from NCFM Medical Memberships and Concierge contracts and NWC annual administration fees, which include bundled products and services that have substantially the same pattern of transfer to the customer, is recognized over the period of delivery, which is the same as the period of the contract (typically, one year). Revenue from prepaid BTG physical therapy bundles, for which performance obligations are satisfied over time as visits are incurred, is recognized based on actual visits incurred in relation to total expected visits. At inception of such contracts, the Company recognizes contract liabilities for the value of services to be provided and, where applicable, contract assets for recoverable amounts incurred to obtain a customer contract that would not have incurred if the contract had not been obtained. The Company believes that these methods provide a faithful depiction of the transfer of services over the term of the performance obligations based on the inputs needed to satisfy the obligation. Revenue for performance obligations satisfied at a point in time, which includes all patient service revenue other than NCFM annual access contracts, NWC annual administration fees, and BTG physical therapy bundles, is recognized when goods or services are provided at the time of the patient visit, and at which time the Company is not required to provide additional goods or services to the patient. The Company determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. Estimates of contractual adjustments and discounts require significant judgment and are based on the Company’s current contractual agreements, its discount policies, and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. There were no material changes during the three months ended March 31, 2024 or 2023 to the judgments applied in determining the amount and timing of patient service revenue. Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows: ● Medicare: Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates; ● Medicaid: Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member. ● Other: Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates. Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Company estimates the transaction price for patients with deductibles and coinsurance and for those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Patient services provided by NCFM, BTG and AEU are provided on a cash basis and not submitted through third party insurance providers. Product and Other Revenue Revenue is derived from the distribution of medical products that are sourced from a third party. The Company recognizes revenue at a point in time when title transfers to customers and the Company has no further obligation to provide services related to such products, which occurs when the product ships. The Company is the principal in its revenue transactions and as a result revenue is recorded on a gross basis. The Company has determined that it controls the ability to direct the use of the product provided prior to transfer to a customer, is primarily responsible for fulfilling the promise to provide the product to its customer, has discretion in establishing prices, and ultimately controls the transfer of the product to the customer. Shipping and handling costs billed to customers are recorded in revenue. Contract liabilities related to product revenue are recognized when payment is received but for which the Company has not met its product fulfillment performance obligation. Sales are made inclusive of sales tax, where such sales tax is applicable. Sales tax is applicable on sales made in the state of Florida, where the Company has physical nexus. The Company has determined that it does not have economic nexus in any other states. The Company does not sell products outside of the United States. The Company maintains a return policy that allows customers to return a product within a specified period of time prior to and subsequent to the expiration date of the product. The Company analyzes the need for a product return allowance at the end of each period based on eligible products. Cash and Cash Equivalents For financial statement purposes, the Company considers all highly liquid investments with original maturities of six months or less to be cash and cash equivalents. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company had $-0- and $-0- in cash balances in excess of the FDIC insured limit as of March 31, 2024 and December 31, 2023, respectively. Accounts Receivable Trade receivables related to NWC services billed to third party payors are carried at the estimated collectible amount. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates 61% of total billings. Trade accounts receivable are recorded at this net amount. As of March 31, 2024 and December 31, 2023, the Company’s gross patient services accounts receivable were $40,295 and $34,481, respectively, and net patient services accounts receivable were $33,620 and $20,861, respectively, based upon net reporting of accounts receivable. As of March 31, 2024 and December 31, 2023, the Company’s allowance for doubtful accounts was $-0- and $-0-, respectively. Other Comprehensive Income The Company does not have any activity that results in Other Comprehensive Income. Leases Upon transition under ASU 2016-02, the Company elected the suite of practical expedients as a package applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. For new leases, the Company will determine if an arrangement is or contains a lease at inception. Leases are included as ROU assets within other assets and ROU liabilities within accrued expenses and other liabilities and within other long-term liabilities on the Company’s consolidated balance sheets. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s leases do not provide an implicit rate. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. See Note 8 for more complete details on balances as of the reporting periods presented herein. Inventory Inventory consisting of supplements, is stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method. Outdated inventory is directly charged to cost of goods sold. Intangible Assets The Company recognizes an acquired intangible whenever the intangible arises from contractual or other legal rights, or whenever it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their estimated useful lives unless the estimated useful life is determined to be indefinite. Amortizable intangible assets are being amortized primarily over useful lives of five years. The straight-line method of amortization is used as it has been determined to approximate the use pattern of the assets. Impairment losses are recognized if the carrying amount of an intangible that is subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value. Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. The Company relies on a sole supplier for the fulfillment of substantially all of its product sales made through MOD. Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. Fair Value of Assets and Liabilities Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs: ● Level 1 – Fair value based on quoted prices in active markets for identical assets or liabilities; ● Level 2 – Fair value based on significant directly observable data (other than Level 1 quoted prices) or significant indirectly observable data through corroboration with observable market data. Inputs would normally be (i) quoted prices in active markets for similar assets or liabilities, (ii) quoted prices in inactive markets for identical or similar assets or liabilities or (iii) information derived from or corroborated by observable market data; ● Level 3 – Fair value based on prices or valuation techniques that require significant unobservable data inputs. Inputs would normally be a reporting entity’s own data and judgments about assumptions that market participants would use in pricing the asset or liability. The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a binomial lattice option pricing model to estimate the fair value of options, warrants, beneficial conversion features and other Level 3 financial assets and liabilities. The Company believes that the binomial lattice model results in the best estimate of fair value because it embodies all of the requisite assumptions (including the underlying price, exercise price, term, volatility, and risk-free interest-rate) necessary to fairly value these instruments and, unlike less sophisticated models like the Black-Scholes model, it also accommodates assumptions regarding investor exercise behavior and other market conditions that market participants would likely consider in negotiating the transfer of such an instruments. Stock-Based Compensation The Company accounts for stock-based compensation to employees and nonemployees under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718 “Compensation – Stock Compensation” using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company uses a binomial lattice pricing model to estimate the fair value of options and warrants granted. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. No income tax has been provided for the three months ended March 31, 2024 since the Company sustained a loss in that period. No income tax was provided for the three months ended March 31, 2023 because the Company had sufficient operating loss carryforwards to offset any net income for the full year 2023, including income from capital gains related to the disposal of discontinued operations. The Company recognized net loss for the full year 2023. Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, management has determined a full valuation allowance for the deferred tax assets, since it is more likely than not that the deferred tax assets will not be realizable. Recurring Fair Value Measurements The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, accounts payable, and accrued liabilities approximated their fair value. Net Income (Loss) per Share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the three months ended March 31, 2024 and 2023, the Company reported a loss from continuing operations. As a result, diluted net income (loss) per common share is computed in the same manner as basic net income (loss) per common share, even though the Company had net income in the three months ended March 31, 2023 after adjusting for discontinued operations. The Company excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of March 31, 2024 and December 31, 2023, potentially dilutive securities were comprised of (i) 85,357,246 and 77,414,648 warrants outstanding, respectively, (ii) 7,063,146 and 5,093,738 stock options outstanding, respectively, (iii) 1,026,324 and 1,484,488 unissued shares subject to future vesting requirements granted pursuant to the Company’s Employee Incentive Plan, (iv) up to 1,055,536 and 2,764,352 common shares issuable that are earned but not paid under consulting and director compensation arrangements, and (v) up to 13,750,000 and 13,750,000 shares of common stock issuable upon conversion of Series B Preferred. Common Stock Awards The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded on the consolidated statement of operations in the same manner and charged to the same account as if such settlements had been made in cash. From time to time, the Company also issues stock awards settleable in a variable number of common shares. Such awards are classified as liabilities until such time as the number of shares underlying the grant is determinable. Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes pricing model as of the measurement date. The Company uses a binomial lattice pricing model to estimate the fair value of compensation options and warrants. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period, or at the date of issuance, if there is not a service period. Certain of the Company’s warrants include a so-called down round provision. The Company accounts for such provisions pursuant to ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has three operating segments: Health Services (multi-specialty medical group including the NWC GYN practice, the NCFM functional medicine practice, the BTG physical therapy practice, and the AEU cosmetic services practice), Digital Healthcare (develops and markets the “HealthLynked Network,” an online personal medical information and record archive system), and Medical Distribution (comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices). The Company’s ACO/MSO segment was sold on January 17, 2023. As described in further detail in Note 4, “Discontinued Operations,” this unit’s assets and liabilities are classified as held for sale as of December 31, 2022 and the unit’s results of operations are classified as “Income (loss) from operations of discontinued operations” in the three months ended March 31, 2024 and 2023. Recently Adopted Pronouncements In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments.” The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. The Company adopted this standard for the year ended December 31, 2023. The adoption did not have a material effect on the Company’s consolidated financial statements. In October 2021, the FASB issued guidance which requires companies to apply Topic 606, Revenue from Contracts with Customers In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard in the three months ended March 31, 2024. The adoption did not have a material effect on the Company’s consolidated financial statements. In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard in the three months ended March 31, 2024. The adoption did not have a material effect on the Company’s consolidated financial statements. No other new accounting pronouncements were issued or became effective in the period that had, or are expected to have, a material impact on our consolidated Financial Statements.

Liquidity and Going Concern Ana

Liquidity and Going Concern Analysis	3 Months Ended
	Mar. 31, 2024
Liquidity and Going Concern Analysis [Abstract]
LIQUIDITY AND GOING CONCERN ANALYSIS	NOTE 3 – LIQUIDITY AND GOING CONCERN ANALYSIS Under ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. Pursuant to ASU 2014-15, in evaluating the Company’s ability to continue as a going concern, management considered the conditions and events that could raise substantial doubt about the Company’s ability to continue as a going concern within 12 months after the Company’s financial statements were issued (May 15, 2025). Management considered the Company’s current financial condition and liquidity sources, including current funds available, forecasted future cash flows and the Company’s obligations due before May 15, 2025. The Company is subject to a number of risks, including uncertainty related to product development and generation of revenues and positive cash flow from its Digital Healthcare Division and a dependence on outside sources of capital. The attainment of profitable operations is dependent on future events, including obtaining adequate financing to fulfill the Company’s growth and operating activities and generating a level of revenues adequate to support the Company’s cost structure. As of March 31, 2024, the Company had cash balances of $23,491, a working capital deficit of $798,224 and an accumulated deficit of $43,420,854. For the three months ended March 31, 2024, the Company had a net loss of $1,387,718 and used cash from operating activities of $854,855. The Company expects to continue to incur net losses and have significant cash outflows for at least the next 12 months. Management has evaluated the significance of the conditions described above in relation to the Company’s ability to meet its obligations and concluded that, without additional funding, the Company will not have sufficient funds to meet its obligations within one year from the date the consolidated financial statements were issued. As described further in Note 4, “Discontinued Operations,” on January 17, 2023, the Company entered into the AHP Merger Agreement, pursuant to which the Buyer agreed to buy, and the Company agreed to sell, AHP. The Company received $750,000 upon signing of the AHP Merger Agreement, the $31,381 Stub Period Reimbursement (defined below) in March 2023, $1,750,000 ($1,540,000 net after commissions) during June, July and August 2023 for meeting 100% of the participating physician transfer milestones outlined in the AHP Merger Agreement, and $1,873,993 ($1,186,231 net after commissions and other expenses) related to AHP’s Plan Year 2022 MSSP shared savings. The Company may also receive future proceeds under the AHP Merger Agreement comprised of (i) up to $500,000 from the Buyer’s plan year 2023 (and if necessary, 2024) MSSP Shared Savings to reimburse amounts advanced to participating physicians at signing that would be received in October 2024, and (ii) proceeds from sale of shares of the Buyer’s common stock if the Buyer completes an initial public offering by February 1, 2025. During the three months ended March 31, 2024, the Company also (i) received net proceeds from the issuance of notes payable to related parties and third parties totaling $500,000 and made repayments on existing and new notes payable to related parties and third parties totaling $221,278, and (ii) received $355,000 proceeds from the sale of its common stock. On July 5, 2022, the Company entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“Yorkville”) (See Note 13, “Shareholders’ Equity,” below for additional information on the SEPA). Pursuant to the SEPA, the Company shall have the right to sell to Yorkville up to 30,000,000 of its shares of common stock, par value $0.0001 per share, at the Company’s request any time during the three-year commitment period set forth in the SEPA. Because the purchase price per share to be paid by Yorkville for the shares of common stock sold by the Company to Yorkville pursuant to the SEPA, if any, will fluctuate based on the market prices of the Company’s common stock during the applicable pricing period, the Company cannot reliably predict the actual purchase price per share to be paid by Yorkville for those shares, or the actual gross proceeds to be raised by the Company from those sales, if any. During the three months ended March 31, 2023, the Company sold 225,000 shares of common stock under the SEPA, receiving $18,765 in proceeds, all of which was applied to the balance of a then-outstanding promissory note payable to Yorkville. The Company has not made any draws pursuant to the SEPA since January 2023. Without raising additional capital, either via additional advances made pursuant to the SEPA or from other sources, there is substantial doubt about the Company’s ability to continue as a going concern through May 15, 2025. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of presentation contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2024
Discontinued Operations [Abstract]
DISCONTINUED OPERATIONS	NOTE 4 – DISCONTINUED OPERATIONS Description of Transaction During the fourth quarter of 2022, the Board approved a plan to sell the Company’s ACO/MSO Division, which assists physician practices in providing coordinated and more efficient care to patients via the MSSP as administered by the CMS, which rewards providers for efficiency in patient care. On January 17, 2023, the Company entered into the AHP Merger Agreement, pursuant to which the Buyer agreed to buy, and the Company agreed to sell, AHP (the “AHP Sale”). Pursuant to the terms of the AHP Merger Agreement, the Company received or will receive the following consideration: (1) $750,000 in cash paid upon signing of the definitive agreement (received January 18, 2023) (the “Upfront Cash Consideration”); (2) the Buyer shall reimburse the Company for expenses incurred by the Company in operating AHP from January 1, 2023 to January 16, 2023 (the “Stub Period Reimbursement”)($31,381 paid in March 2023); (3) up to $1,750,000 net incremental cash based on the agreement to participate in Buyer’s ACO by AHP’s existing physician practices or newly added practices, scaled based on the number of covered patients transferred to PBACO by July 31, 2023 (the “Incremental Cash Consideration”), of which $1,225,000 ($1,180,000 net after commissions) was received in June 2023 and $150,000 ($120,000 net after commissions) was received in July 2023; (4) net proceeds, including allocation for expenses, from any MSSP Shared Savings related to AHP’s plan year 2022 (the “2022 MSSP Consideration”), of which the Company realized gross receipts of $1,873,993 and net proceeds of $1,186,231 after payments to participating physicians and commissions in October 2023; (5) $500,000 of the Incremental Cash Consideration will be allocated to AHP’s participating physicians upon receipt and will be reimbursed to HealthLynked by the Buyer in 2024 from the Buyer’s plan year 2023 (and if necessary, 2024) MSSP Shared Savings (the “Physician Advance Consideration”); and (6) in the event that Buyer completes a planned initial public offering (“IPO”) by February 1, 2025, shares in the public entity at the time of the IPO with a value equal to AHP’s 2021 earnings before interest, taxes depreciation and amortization (“EBITDA”) times the multiple of EBITDA used to value the public entity’s IPO shares, net of any cash consideration previously paid by the Buyer and subject to vesting requirements detailed in the AHP Merger Agreement (the “IPO Share Consideration”). The Company is also required to indemnify the Buyer against liabilities arising from Buyer’s operation of AHP prior to the Buyer’s IPO date, less a deductible equal to 1% of the aggregate merger consideration (the “Indemnification Clause”). In the event Buyer goes public through means other than an IPO, the parties agreed to modify the terms of the IPO Share Consideration to implement such alternate structure. In the event Buyer does not go public by IPO or other means by February 1, 2025, the Company receives no IPO Share Consideration, and the Transaction consideration is capped at the cash consideration of up to $3,000,000 plus the MSSP Consideration. Any participating physician advances will be repaid to the Company out of AHP’s 2023 performance year MSSP Shared Savings, which would be received in 2024. Pursuant to the terms of the Merger Agreement, formal transfer of the equity ownership of AHP from the Company to the Buyer will occur at the earlier of (i) Buyer’s IPO, (ii) Buyer going public by other means, or (iii) if Buyer does not go public, on February 1, 2025. Until that time, the Company has the right, but not the obligation, to reacquire AHP for a price equal to any consideration already paid by the Buyer for AHP, plus all expenses incurred by Buyer in operating AHP after January 16, 2023. Concurrent with the AHP Merger Agreement, AHP and the Buyer also entered into a Management Services Agreement (the “MSA”), pursuant to which the Buyer assumed full control of managing AHP’s business operations and paying AHP’s operating expenses after January 16, 2023. The term of the MSA is from January 17, 2023 to August 1, 2024, which is the latest date that equity ownership of AHP can transfer from the Company to the Buyer. The Buyer agreed in the Merger Agreement to reimburse the Company for reasonable expenses incurred by the Company in operating AHP from January 1, 2023 to January 16, 2023, which we refer to as the Stub Period Reimbursement, during which time the Company had operational and financial control of AHP and CHM. Concurrent with the AHP Merger Agreement and the MSA, and as a result of the Buyer assuming control and responsibility of AHP’s operations, the Company discontinued its operations of CHM. Discontinued Operations The Company has classified the results of the ACO/MSO Division as discontinued operations in the accompanying consolidated statement of operations for all periods presented. No assets or liabilities were classified as held for sale as of March 31, 2024 or December 31, 2023. The financial results of the ACO/MSO Division are presented as income (loss) from discontinued operations, net of income taxes on our consolidated statement of operations. The following table presents financial results of the ACO/MSO Division for the three months ended March 31, 2024: Three Months Ended 2024 2023 Revenue: Consulting revenue $ --- $ 23,646 Total revenue --- 23,646 Operating Expenses and Costs: Medicare shared savings expenses --- 67,935 Loss from operations of discontinued operations before income taxes --- (44,289 ) Provision for income taxes --- --- Loss from discontinued operations, net of income taxes $ --- $ (44,289 ) Net cash used in operations of the ACO/MSO Division was $-0- and $47,163 in the three months ended March 31, 2024 and 2023, respectively. There were no cash flows from investing or financing activities of the ACO/MSO Division in the three months ended March 31, 2024 and 2023. Derecognition and Gain from Disposal of Discontinued Operations As a result of the AHP Sale and pursuant to the terms and conditions of the AHP Merger Agreement and the MSA, the Company ceased to have a controlling financial interest in AHP as of January 17, 2023. Accordingly, in connection with the transaction, the Company deconsolidated AHP as of January 17, 2023. In connection with the deconsolidation, the Company recognized the fair value of consideration received and receivable from the AHP Sale, recognized an indemnification liability related to potential claims resulting from the AHP Sale, derecognized the carrying value of assets and liabilities transferred to the Buyer or otherwise derecognized in connection with in the AHP Sale, and recorded a gain on sale for the excess of consideration received over carrying value of assets derecognized and liabilities recognized. The Company elected to record the contingent portion of consideration receivable at fair value on the sale date pursuant to the guidance in FASB Emerging Issues Task Force Issue 09-4, “Seller Accounting for Contingent Consideration,” (“EITF 09-4”). The fair value of consideration received and receivable is shown in the following table: Upfront Cash Consideration paid at signing $ 750,000 Incremental Cash Consideration 1,311,567 IPO Share Consideration 1,463,517 2022 MSSP Consideration 312,987 Physician Advance Consideration 199,645 Stub Period Reimbursement 31,381 Total fair value of contingent consideration receivable 3,319,097 Total fair value of consideration received and receivable $ 4,069,097 The fair value of contingent consideration receivable was determined using an expected present value approach, which applies a discount rate to a probability-weighted stream of net cash flows based on multiple scenarios, as estimated by management. As such, the fair values of contingent consideration receivable rely on significant unobservable inputs and assumptions and there is uncertainty in the expected future cash flows used in the fair valuation. Significant assumptions related to the valuation of contingent consideration receivable include the likelihood of a Buyer IPO, the valuation of the Buyer’s common stock in a potential IPO, the likelihood that AHP would meet its performance benchmarks to the extent that it will receive shared savings for plan year 2022, the likelihood that AHP under the management of the Buyer would receive sufficient shared savings in plan years 2023 and/or 2024 to pay the Physician Advance Consideration, and the likelihood that the Company would be able to transfer or add new participating physicians to AHP before July 31, 2023 in order to collect the Incremental Cash Consideration. The book value of the assets and liabilities derecognized on January 17, 2023 in connection with the sale were as follows: Prepaid expenses $ 1,500 Intangible asset - ACO physician contract 1,073,000 Goodwill 381,856 Contract liability (20,278 ) Contingent acquisition consideration (185,024 ) Net Book Value of Assets and Liabilities Sold $ 1,251,054 Prepaid expenses are prepaid services from which the Buyer will benefit following the AHP Sale. Intangible assets and goodwill represent the carrying value of assets recorded at the time the Company acquired CHM and AHP in 2020 (the “Original Acquisition”). Contract liability represents remaining unearned revenue for which the Buyer is required to provide the performance obligations after January 17, 2023. In connection with the AHP Sale, the remaining value of contingent acquisition consideration (“CAC”) related to the Original Acquisition was written off. After recording the fair value of consideration and derecognition of assets and liabilities, and an estimated liability related to the Indemnification Clause, the Company recorded a gain from disposal of discontinued operations in the amount of $2,674,069 in the three months ended Mach 31, 2023 as follows: Total fair value of consideration received and receivable $ 4,069,097 Less: net book value of assets and liabilities sold (1,251,054 ) Less: fair value of Indemnification Clause (143,974 ) Gain from disposal of discontinued operations $ 2,674,069 After January 17, 2023, and as prescribed under EITF 09-4, the Company has elected to subsequently treat the contingent consideration receivable using gain contingency guidance and only record a gain or loss when the contingency is resolved. Accordingly, the Company does not prospectively remeasure the fair value of contingent consideration receivable each reporting period. Receipts of Contingent Sale Consideration Receivable The Company received $750,000 upon signing of the AHP Merger Agreement, the $31,381 Stub Period Reimbursement in March 2023, $1,750,000 ($1,540,000 net after commissions) Incremental Cash Consideration during June, July and August 2023 for meeting 100% of the participating physician transfer milestones outlined in the AHP Merger Agreement, and $1,873,993 ($1,186,231 net after commissions and other expenses) in October 2023 related to AHP’s Plan Year 2022 MSSP shared savings. The carrying value of the remaining unresolved components of contingent consideration receivable as of March 31, 2024 and December 31, 2023 was as follows: IPO Share Consideration $ 1,463,518 Physician Advance Consideration 199,645 Remaining contingent sale consideration receivable $ 1,663,163

Prepaid Expenses and Other

Prepaid Expenses and Other	3 Months Ended
	Mar. 31, 2024
Prepaid Expenses and Other [Abstract]
PREPAID EXPENSES AND OTHER	NOTE 5 – PREPAID EXPENSES AND OTHER Prepaid and other expenses as of March 31, 2024 and December 31, 2023 were as follows: March 31, December 31, 2024 2023 Insurance prepayments $ 7,791 $ 11,209 Other expense prepayments 22,475 38,391 Rent deposits 50,047 50,547 Contract assets 9,750 5,110 Total prepaid expenses and other 90,063 105,257 Less: long term portion (50,047 ) (50,047 ) Prepaid expenses and other, current portion $ 40,016 $ 55,210 Contract assets relate to amounts incurred to obtain a customer contract that would not have been incurred if the contract had not been obtained, such as commissions, associated with NCFM annual access contracts.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 6 – PROPERTY AND EQUIPMENT Property and equipment as of March 31, 2024 and December 31, 2023 were as follows: March 31, December 31, 2024 2023 Medical equipment $ 496,452 $ 493,854 Furniture, office equipment and leasehold improvements 317,963 317,963 Total property and equipment 814,415 811,817 Less: accumulated depreciation (550,531 ) (521,062 ) Property and equipment, net $ 263,884 $ 290,755 Depreciation expense during the three months ended March 31, 2024 and 2023 was $29,469 and $31,037, respectively.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2024
Intangible Assets and Goodwill [Abstract]
Intangible Assets	NOTE 7 – INTANGIBLE ASSETS Identifiable intangible assets as of March 31, 2024 and December 31, 2023 were as follows: March 31, December 31, 2024 2023 NCFM: Medical database $ 1,101,538 $ 1,101,538 NCFM: Website 41,000 41,000 Total intangible assets 1,142,538 1,142,538 Less: accumulated amortization (315,730 ) (258,690 ) Intangible assets, net $ 826,808 $ 883,848 Intangible assets arose from the acquisition of NCFM in April 2019. The NCFM medical database is being prospectively amortized starting January 1, 2023 over an estimated five-year useful life. The NCFM website began being amortized over a five-year life from the acquisition date. Amortization expense related to intangible assets in the three months ended March 31, 2024 and 2023 was $57,040 and $57,040, respectively. Future amortization expense of intangible assets is expected to be as follows: 2024 (April to December) $ 165,885 2025 220,308 2026 220,308 2027 220,307 Thereafter --- Total future amortization expense $ 826,808

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
LEASES	NOTE 8 – LEASES The Company has separate operating leases, and related amendments thereto, for office space related to its NWC, NCFM, BTG and AEU practices, its corporate headquarters, and a copier lease that expire in July 2026, May 2025, March 2024, March 2026, November 2026, and January 2027, respectively. As of March 31, 2024, the Company’s weighted-average remaining lease term relating to its operating leases was 2.4 years, with a weighted-average discount rate of 15.44%. The table below summarizes the Company’s lease-related assets and liabilities as of March 31, 2024 and December 31, 2023: March 31, December 31, 2024 2023 Lease assets $ 853,525 $ 935,812 Lease liabilities Lease liabilities (short term) $ 332,692 $ 326,033 Lease liabilities (long term) 524,546 613,386 Total lease liabilities $ 857,238 $ 939,419 Lease expense was $129,431 and $111,905 in the three months ended March 31, 2024 and 2023, respectively. Maturities of operating lease liabilities were as follows as of March 31, 2024: 2024 $ 390,027 2025 467,994 2026 335,634 2027 990 Total lease payments 1,194,645 Less interest (337,407 ) Present value of lease liabilities $ 857,238

Accounts Payable, Accrued Expen

Accounts Payable, Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2024
Accounts Payable and Accrued Expenses [Abstract]
ACCOUNTS PAYABLE, ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 9 – ACCOUNTS PAYABLE, ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Amounts related to accounts payable, accrued expenses and other current liabilities as of March 31, 2024 and December 31, 2023 were as follows: March 31, December 31, 2024 2023 Trade accounts payable $ 372,612 $ 251,479 Accrued payroll liabilities 76,646 110,103 Accrued operating expenses 175,349 91,238 Accrued interest 52,287 57,074 Accrued commissions payable from 2022 MSSP Consideration (a) 25,000 100,000 Contingent acquisition consideration payable (b) 2,113 2,189 Product return allowance 1,117 2,095 $ 705,124 $ 614,178 (a) During September 2023, AHP received from the CMS a final determination of AHP’s Plan Year 2022 MSSP shared savings, of which the Company realized gross receipts of $1,873,993 and net proceeds of $1,186,231 after payments to participating physicians and commissions in satisfaction of the 2022 MSSP Consideration. Gross payment was received by the Company in October 2023. As of December 31, 2023, the Company’s remaining accrued commissions and other fees payable resulting from the receipt and prior consideration received in the amount of $100,000, of which $75,000 was paid in the three months ended March 31, 2024. See Note 4 for complete description of the AHP Sale and related consideration. (b) Contingent acquisition consideration reflects the fair value of the final earn-out payment potentially payable related to the Company’s acquisitions of MOD in 2020. All of the remaining $2,113 contingent acquisition consideration related to MOD matures in 2024 based on the performance of the business unit for the year ended December 31, 2024.

Contract Liabilities

Contract Liabilities	3 Months Ended
	Mar. 31, 2024
Contract Assets and Liabilities [Abstract]
CONTRACT LIABILITIES	NOTE 10 – CONTRACT LIABILITIES Amounts related to contract liabilities as of March 31, 2024 and December 31, 2023 were as follows: March 31, December 31, 2024 2023 Patient services paid but not provided - NCFM $ 175,333 $ 95,334 Patient services paid but not provided - BTG 90,599 100,857 Patient services paid but not provided - NWC 64,114 75,438 Unshipped products - MOD 1,394 145 $ 331,440 $ 271,774 Contract liabilities relate to (i) NCFM annual access contracts, including Medical Membership, Concierge Service and Optimal Health 365 Access Plan contracts pursuant to which patients prepay for access to services to be provided at the patient’s request over a period of time, (ii) BTG contracts pursuant to which patients prepay for access to a fixed number of visits used at the patients’ discretion, (iii) NWC annual administration fees, and (iv) MOD sold but unshipped products.

Amounts Due to Related Party an

Amounts Due to Related Party and Related Party Transactions	3 Months Ended
	Mar. 31, 2024
Amounts Due to Related Party and Related Party Transactions [Abstract]
AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS	NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS Amounts due to related parties as of March 31, 2024 and December 31, 2023 were comprised of the following: March 31, December 31, 2024 2023 Note Payable to Dr. Michael Dent, March 2023 $ --- $ 12,601 Note Payable to Dr. Michael Dent, June 2023 --- 26,875 Note Payable to Dr. Michael Dent, December 2023 --- 166,500 Convertible Note Payable I to Dr. Michael Dent, March 2024 150,000 --- Convertible Note Payable II to Dr. Michael Dent, March 2024 350,000 --- Convertible Note Payable III to Dr. Michael Dent, March 2024 199,621 --- Face value of notes payable to related party 699,621 205,976 Less: unamortized discounts (281,579 ) (34,834 ) Notes payable to related party, total 418,042 171,142 Plus deferred compensation payable to Dr. Michael Dent 300,600 300,600 Total due to related party $ 718,642 $ 471,742 Notes Payable to Dr. Michael Dent On November 8, 2022, the Company entered into a Merchant Cash Advance Factoring Agreement with a trust controlled by Dr. Dent, pursuant to which the Company received an advance of $150,000 (the “November MCA”). The Company was required to repay the November MCA at the rate of $3,750 per week until the balance of $195,000 was repaid, which was scheduled for November 2023. At inception, the Company recognized a note payable in the amount of $195,000 and a discount against the note payable of $45,000. The discount was being amortized over the life of the November MCA. The Company made payments totaling $-0- and $33,750 in the three months ended March 31, 2024 and 2023, respectively. Amortization of debt discount was $-0- and $11,219 in the three months ended March 31, 2024 and 2023, respectively. The November MCA was repaid in full during the fourth quarter of 2023. As of March 31, 2024 and December 31, 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively. On December 13, 2022, the Company entered into a Merchant Cash Advance Factoring Agreement with a trust controlled by Dr. Dent, pursuant to which the Company received an advance of $110,000 (the “December MCA”). The Company was required to repay the December MCA at the rate of $2,750 per week until the balance of $143,000 was repaid, which was scheduled for December 2023. In connection with the December MCA, the Company issued 3,142,857 three-year warrants to the holder with an exercise price of $0.035. The fair value of the warrants was $63,420. At inception, the Company recognized a note payable in the amount of $143,000 and a discount against the note payable of $68,281 for the allocated fair value of the original issue discounts and warrants. The discount was being amortized over the life of the December MCA. The Company made payments totaling $-0- and $24,750 in the three months ended March 31, 2024 and 2023, respectively. Amortization of debt discount was $-0- and $17,070 in the three months ended March 31, 2024 and 2023, respectively. The December MCA was repaid in full during the fourth quarter of 2023. As of March 31, 2024 and December 31, 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively. On January 5, 2023, the Company issued an unsecured promissory note to Dr. Dent with a face value of $10,000 (the “$10k Dent Note”). The $10k Dent Note bore interest at a rate of 15% per annum and was scheduled to mature six months from issuance. In connection with the $10k Dent Note, the Company issued 96,154 five-year warrants to the holder with an exercise price of $0.104. The fair value of the warrants was $6,843. At inception, the Company recognized a note payable in the amount of $10,000 and a discount against the note payable of $3,851 for the allocated fair value of the warrants. The discount was to be amortized over the life of the $10k Dent Note. The $10k Dent Note was repaid in full during January 2023. Amortization of debt discount and interest expense prior to repayment were $269 and $53, respectively, in the three months ended March 31, 2023. In connection with the repayment, the Company recognized a loss on extinguishment of debt of $3,582 in the three months ended March 31, 2023. On January 13, 2023, the Company issued an unsecured promissory note to Dr. Dent with a face value of $161,000 (the “January 2023 Dent Note”). Net proceeds were $160,000, taking into account the original issue discount of $1,000. The January 2023 Dent Note bore interest at a rate of 15% per annum and was scheduled to mature six months from issuance. In connection with the January 2023 Dent Note, the Company issued 860,215 three-year warrants to Dr. Dent with an exercise price of $0.093. The fair value of the warrants was $56,123. At inception, the Company recognized a note payable in the amount of $161,000 and a discount against the note payable of $42,553 for the allocated fair value of the original issue discount and warrants. The discount was to be amortized over the life of the January 2023 Dent Note. The January 2023 Dent Note was repaid in full during January 2023. Amortization of debt discount and interest expense prior to repayment were $1,373 and $397, respectively, in the three months ended March 31, 2023. In connection with the repayment, the Company recognized a loss on extinguishment of debt of $41,181 in the three months ended March 31, 2023. On February 14, 2023, the Company issued an unsecured promissory note to Dr. Dent with a face value of $186,000 (the “February 2023 Dent Note”). Net proceeds were $185,000 after an original issue discount of $1,000. The February 2023 Dent Note bore interest at a rate of 15% per annum and matured six months from issuance. In connection with the February 2023 Dent Note, the Company issued 685,185 three-year warrants to Dr. Dent with an exercise price of $0.135. The fair value of the warrants was $66,136. At inception, the Company recognized a note payable in the amount of $186,000 and a discount against the note payable of $50,989 for the allocated fair value of the original issue discounts and warrants. The discount was amortized over the life of the February 2023 Dent Note. No payments were made on the February 2023 Dent Note in the three months ended March 31, 2023. Amortization of debt discount and interest expense were $1,373 and $3,440, respectively, in the three months ended March 31, 2023. On March 14, 2023, the Company issued a promissory note payable to a trust controlled by Dr. Dent with a stated principal amount of $112,510 and prepaid interest of $13,501 for total scheduled repayments of $126,011 (the “March 2023 Dent Note”). The March 2023 Dent Note had an original issue discount of $12,510, resulting in net proceeds to the Company of $100,000. At inception, the Company recognized a note payable in the amount of $126,011 and a discount against the note payable of $26,011. The March 2023 Dent Note did not bear interest in excess of the prepaid interest and original issue discount and matured on March 14, 2024. The Company was required to make 10 monthly payments of $12,601 starting April 30, 2023. At inception, the Company recorded a discount against the note of $26,011, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. The March 2023 Dent Note gave the holder a conversion right at a 15% discount to the market price of the Company’s common stock in the event of default. The Company determined that the fair value of the contingent conversion option was immaterial and therefore did not allocate any value related to the option to the proceeds received. The Company made payments totaling $12,601 and $-0- in the three months ended March 31, 2024 and 2023, respectively. Amortization of debt discount was $2,504 and $1,292 in the three months ended March 31, 2024 and 2023, respectively. The March 2023 Dent Note was repaid in January 2024. On June 26, 2023, the Company issued an unsecured promissory note to Dr. Michael Dent with a face value of $25,000 (the “June 2023 Dent Note”). The June 2023 Dent Note bore a fixed interest charge of $1,875 (15% per annum) and matured on December 26, 2023. At inception, the Company recorded a note payable in the amount of $26,875 and a discount against the note of $1,875. The Company made payments totaling $25,000 and $-0- in the three months ended March 31, 2024 and 2023, respectively. Amortization of debt discount was $-0- and $1,292 in the three months ended March 31, 2024 and 2023, respectively. The June 2023 Dent Note was repaid in January 2024. On December 1, 2023, the Company issued an unsecured promissory note to a trust controlled by Dr. Dent with a face value of $150,000 (the “December 2023 Dent Note”). The December 2023 Dent Note bore a fixed interest charge of $15,000 (10% per annum) and $1,500 in fixed fees and matured on February 28, 2024. The Company received net proceeds of $150,000 after discounts and fees. In connection with the note, the Company issued 1,500,000 five-year warrants to the holder with an exercise price of $0.06. The fair value of the warrants was $32,269. At inception, the Company recorded a note payable in the amount of $166,500 and a discount against the note payable of $48,769 for the allocated fair value of the original issue discount and warrants. The Company made payments totaling $-0- and $-0- in the three months ended March 31, 2024 and 2023, respectively, on the December 2023 Dent Note. Amortization of debt discount was $32,330 and $-0- in the three months ended March 31, 2024 and 2023, respectively. On March 27, 2024, the December 2023 Dent Note was refinanced and replaced with the March 2024 Dent Note III as described below. No loss on extinguishment of debt was recognized in the three months ended March 31, 2024 because the discount was fully amortized at the time of the refinancing. On March 27, 2024, the Company issued to a trust controlled by Dr. Michael Dent three separate notes payable as follows: (1) a note payable with a principal of $350,000, an interest rate of 12% per annum, and a maturity date of June 27, 2024 (the “March 2024 Dent Note I”), (2) a note payable with a principal of $150,000, an interest rate of 12% per annum, and a maturity date of August 24, 2024 (the “March 2024 Dent Note II”), and (3) a note payable with a principal of $166,500, an interest rate of 12% per annum, and a maturity date of August 28, 2024 (the “March 2024 Dent Note III”, and collectively, the “March 2024 Dent Notes”). The full amount of principal and accrued interest on each of the March 2024 Dent Notes is due at the respective maturity date of each note. Each of the March 2024 Dent Notes is convertible at any time at the holder’s option into shares of Company common stock at a fixed conversion price of $0.0573 per share. In connection with the issuance of the March 2024 Dent Notes, the Company also issued to the holder a ten-year warrant to purchase 6,660,000 shares of the Company’s common stock at an exercise price of $0.06 per share (the “March 2024 Warrant”). The fair value of the March 2024 Warrant was $254,345. Net proceeds from the March 2024 Dent Note I were $350,000. At inception, the Company recorded a discount of $203,588, representing the allocated fair value of the beneficial conversion feature (“BCF”) and the portion of the fair value of the March 2024 Warrant allocated to the March 2024 Dent Note I. The discount is being amortized over the life of the note. Amortization expense related to the note discount was $8,852 and $-0- in the three months ended March 31, 2024 and 2023, respectively. The Company made no payments against the March 2024 Dent Note I in the three months ended March 31, 2024 or 2023. As of March 31, 2024 and December 31, 2023, remaining principal payments were $350,000 and $-0-, respectively, the net carrying value was $155,264 and $-0-, respectively, and accrued interest was $460 and $-0-, respectively. Net proceeds from the March 2024 Dent Note II were $150,000. At inception, the Company recorded a discount of $89,222, representing the allocated fair value of the BCF and the portion of the fair value of the March 2024 Warrant allocated to the March 2024 Dent Note II. The discount is being amortized over the life of the note. Amortization expense related to the note discount was $2,379 and $-0- in the three months ended March 31, 2024 and 2023, respectively. The Company made no payments against the March 2024 Dent Note II in the three months ended March 31, 2024 or 2023. As of March 31, 2024 and December 31, 2023, remaining principal payments were $150,000 and $-0-, respectively, the net carrying value was $63,157 and $-0-, respectively, and accrued interest was $197 and $-0-, respectively. The March 2024 Dent Note III refinanced the previously issued December 2023 Dent Note in the same principal amount of $166,500. Because the two notes were determined to be substantially different, the issuance of the March 2024 Dent Note III and repayment of the December 2023 Dent Note was treated as an extinguishment and reissuance. Accordingly, the Company recognized a loss on debt extinguishment of $96,660 on the transaction date, comprised of $63,539 for the portion of the fair value of the March 2024 Warrant allocated to the March 2024 Dent Note III and $33,121 for the excess of the fair value of the March 2024 Dent Note III over the carrying value of the refinanced December 2023 Dent Note. The March 2024 Dent Note III was recorded at its fair value of $199,621 and will be revalued at future period ends. As of March 31, 2024 and December 31, 2023, remaining principal payments were $166,500 and $-0-, respectively, the carrying value was $199,621 and $-0-, respectively, and accrued interest was $219 and $-0-, respectively. Interest accrued on notes and convertible notes payable to related parties as of March 31, 2024 and December 31, 2023 was $3,202 and $7,456, respectively. Interest expense on the loans was $3,202 and $3,890 in the three months ended March 31, 2024 and 2023, respectively. Deferred Compensation Payable to Dr. Michael Dent There was no activity related to deferred compensation payable to Dr. Michael Dent and therefore, as of March 31, 2024 and December 31, 2023, the balance was $300,600 and $300,600, respectively. Other Related Transactions Our outside directors each receive compensation equal to $20,000 in shares of restricted stock per annum. As of March 31, 2024 and December 31, 2023, we had 816,328 and 408,164 shares, respectively, issuable to our directors under such compensation arrangements. During the three months ended March 31, 2024 and 2023, the Company paid Dr. Dent’s spouse $39,038 and $27,885, respectively, in consulting fees pursuant to a consulting agreement.

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2024
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 12 – NOTES PAYABLE Notes payable as of March 31, 2024 and December 31, 2023 were as follows: March 31, December 31, 2024 2023 SBA Disaster Relief Loans $ 450,000 $ 450,000 1800 Diagonal Note Payable III, August 2023 64,853 97,279 Yorkville Note Payable III, November 2023 226,800 302,400 1800 Diagonal Note Payable III, December 2023 113,482 162,131 Yorkville Note Payable III, December 2023 162,000 189,000 Face value of notes payable 1,017,135 1,200,810 Less: unamortized discounts (104,288 ) (166,487 ) Notes payable, total 912,847 1,034,323 Less: long term portion (450,000 ) (450,000 ) Notes payable, current portion $ 462,847 $ 584,323 Government Notes Payable During June, July and August 2020, the Company and its subsidiaries received an aggregate of $450,000 in Disaster Relief Loans from the SBA. The loans bear interest at 3.75% per annum and mature 30 years from issuance. Mandatory principal and interest payments were originally scheduled to begin 12 months from the inception date of each loan and were subsequently extended by the SBA until 30 months from the inception date. Installment payments, which are first applied to accrued but unpaid interest and then to principal, began in 2023. Interest accrued on SBA loans as of March 31, 2024 and December 31, 2023 was $27,095 and $27,628, respectively. Interest expense on the loans was $6,046 and $4,219 in the three months ended March 31, 2024 and 2023, respectively. Payments against interest were $6,579 and $5,117 in the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024 and December 31, 2023, remaining principal payments were $450,000 and $450,000, respectively, and the net carrying value was $450,000 and $450,000, respectively. Other Notes Payable On July 19, 2022, pursuant to a Note Purchase Agreement between the Company and Yorkville, dated July 5, 2022, the Company issued to Yorkville a promissory note (the “Promissory Note”) with an initial stated principal amount equal to $550,000 at a purchase price equal to the principal amount of the Promissory Note less any original issue discounts and fees. The Promissory Note included a 5% original issue discount, accrues interest at a rate of 0%, and was scheduled to mature on January 19, 2023. The Company received net proceeds of $522,500. Each payment included a 2% payment premium, totaling $561,000 in total cash repayments. At inception, the Company recorded a discount against the note of $38,500, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. On November 15, 2022, the Company and Yorkville entered into an Amended and Restated Note (the “Amended Note”) to, among other things, extend the original note’s maturity date of January 19, 2023 to March 15, 2023. Amortization expense related to the discount was $-0- and $4,748 in the three months ended March 31, 2024 and 2023, respectively. During the three months ended March 31, 2024 and 2023, the Company made payments of $-0- and $168,300 against the Promissory Note, including $18,765 applied from proceeds of sales of common stock under the SEPA. The Amended Note was repaid in March 2023. On October 21, 2022, the Company issued a promissory note payable to an investor in the principal amount of $144,760 (the “October 2022 Note”). The October 2022 Note had an original issue discount of $15,510 and fees of $4,250, resulting in net proceeds to the Company of $125,000. The October 2022 Note did not bear interest in excess of the original issue discount and had a maturity date of October 31, 2023. The Company was required to make 10 monthly payments of $16,213 starting November 30, 2022 and ending August 31, 2023. At inception, the Company recorded a discount against the note of $37,131, representing the difference between the total required repayments and the net proceeds received, which was amortized over the repayment period. During the three months ended March 31, 2024 and 2023, amortization expense related to the note discount was $-0- and $10,745, respectively, and the Company made payments of $-0- and $32,426, respectively, against the outstanding balance. The October 2022 Note was repaid in August 2023. On March 10, 2023, the Company issued a promissory note payable to an investor with a stated principal amount of $116,760 and prepaid interest of $14,011 for total repayments of $130,771 (the “March 2023 Note”). The March 2023 Note had an original issue discount of $12,510 and fees of $4,250, resulting in net proceeds to the Company of $100,000. The March 2023 Note did not bear interest in excess of the original issue discount and matured on March 10, 2024. The Company was required to make 10 monthly payments of $13,077 starting April 30, 2023. At inception, the Company recorded a discount against the note of $30,771, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. Amortization expense related to the note discount was $-0- and $1,529 in the three months ended March 31, 2024 and 2023, respectively. The Company made no payments against the outstanding balance in the three months ended March 31, 2024 or 2023. The final installment payment was made in December 2023. On November 4, 2022, AEU borrowed a gross amount of $41,009 from a third-party lender, receiving net proceeds of $35,800 after fees and discounts (the “AEU Loan”). At inception of the note, the Company recognized a discount of $5,209. During the three months ended March 31, 2024 and 2023, amortization expense related to the note discount was $-0- and $2,367, respectively, and the Company made payments of $-0- and $18,632, respectively, against the outstanding balance. The AEU Loan was repaid in June 2023. On August 8, 2023, the Company issued a promissory note payable to an investor with a stated principal amount of $144,760 and prepaid interest of $17,371 for total repayments of $162,131 (the “August 2023 Note”). The August 2023 Note had an original issue discount of $15,510 and fees of $4,250, resulting in net proceeds to the Company of $125,000. The August 2023 Note does not bear interest in excess of the original issue discount and matures on June 30, 2024. The Company is required to make 10 monthly payments of $16,213 starting September 30, 2023 and ending on June 30, 2024. At inception, the Company recorded a discount against the note of $37,131, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. Amortization expense related to the note discount was $10,365 and $-0- in the three months ended March 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $32,426 and $-0- in the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024 and December 31, 2023, remaining payments were $64,853 and $97,279, respectively, and the net carrying value was $54,488 and $76,549, respectively. The August 2023 Note gives the holder a conversion right at a 15% discount to the market price of the Company’s common stock in the event of default. The Company determined that the fair value of the contingent conversion option was immaterial and therefore did not allocate any value related to the option to the proceeds received. As of March 31, 2024, the August 2023 Note was not in default and the Company was in compliance with the stated loan requirements. On November 3, 2023, the Company issued to Yorkville a note payable (the “November 2023 Note”) with an initial principal amount equal to $350,000 at a purchase price equal to the principal amount of the November 2023 Note less any original issue discounts and fees. The Company received net proceeds of $317,000. The November 2023 Note is scheduled to mature on September 3, 2024. The November 2023 Note accrues interest at a rate of 0% but was issued with an 8% original issue discount and is scheduled to be repaid in ten equal semi-monthly installments beginning on December 3, 2023, with each payment including an 8% payment premium, totaling $378,000 in cash repayments. At inception, the Company recorded a discount against the note of $61,000, representing the difference between the total required repayments and the net proceeds received, which was being amortized over the repayment period. Amortization expense related to the note discount was $18,200 and $-0- in the three months ended March 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $75,600 and $-0- in the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024 and December 31, 2023, remaining payments were $226,800 and $302,400, respectively, and the net carrying value was $195,600 and $253,000, respectively. On December 12, 2023, the Company issued a promissory note payable to an investor with a stated principal amount of $144,760 and prepaid interest of $17,371 for total repayments of $162,131 (the “December 2023 Note I”). The December 2023 Note I had an original issue discount of $15,510 and fees of $4,250, resulting in net proceeds to the Company of $125,000. The December 2023 Note I does not bear interest in excess of the original issue discount and matures on October 15, 2024. The Company is required to make 10 monthly payments of $16,213 starting January 15, 2024 and ending on October 15, 2024. At inception, the Company recorded a discount against the note of $37,131, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. Amortization expense related to the note discount was $10,971 and $-0- in the three months ended March 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $48,649 and $-0- in the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024 and December 31, 2023, remaining payments were $113,482 and $162,131, respectively, and the net carrying value was $89,612 and $127,291, respectively. The December 2023 Note I gives the holder a conversion right at a 15% discount to the market price of the Company’s common stock in the event of default. The Company determined that the fair value of the contingent conversion option was immaterial and therefore did not allocate any value related to the option to the proceeds received. As March 31, 2024, the December 2023 Note I was not in default and the Company was in compliance with the stated loan requirements. On December 13, 2023, the Company issued to Yorkville a convertible note (the “December 2023 Note II”) with an initial principal amount equal to $175,000 at a purchase price equal to the principal amount of the December 2023 Note II less any original issue discounts and fees. The Company received net proceeds of $156,000. The December 2023 Note II is scheduled to mature on September 3, 2024. The December 2023 Note II accrues interest at a rate of 0% but was issued with an 8% original issue discount and is scheduled to be repaid in ten equal semi-monthly installments beginning on March 3, 2024, with each payment including an 8% payment premium, totaling $189,000 in cash repayments. The December 2023 Note II is convertible at any time at the holder’s option into shares of Company common stock at a fixed conversion price of $0.05 per share. At inception, the Company recorded a discount against the note of $66,000, representing the fair value of the conversion option and the difference between the total required repayments and the net proceeds received. The discount is being amortized over the repayment period. Amortization expense related to the note discount was $22,664 and $-0- in the three months ended March 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $27,000 and $-0- in the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024 and December 31, 2023, remaining payments were $162,000 and $189,000, respectively, and the net carrying value was $123,147 and $127,483, respectively.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2024
Shareholders' Equity [Abstract]
SHAREHOLDERS’ EQUITY	NOTE 13 – SHAREHOLDERS’ EQUITY SEPA Advances On July 5, 2022, the Company entered into the SEPA with Yorkville, pursuant to which the Company shall have the right, but not the obligation, to sell to Yorkville up to 30,000,000 of its shares of common stock, par value $0.0001 per share, at the Company’s request any time during the commitment period commencing on July 5, 2022 and terminating on the earliest of (i) the first day of the month following the 36-month anniversary of the SEPA and (ii) the date on which Yorkville shall have made payment of any advances requested pursuant to the SEPA for shares of the Company’s common stock equal to the commitment amount of 30,000,000 shares of common stock. Each SEPA advance (an “Advance”) may be for a number of shares of common stock with an aggregate value of up to greater of: (i) an amount equal to thirty percent (30%) of the aggregate daily volume traded of the Company’s common stock for the three (3) trading days immediately preceding notice from the Company of an Advance, or (ii) 2,000,000 shares of common stock. The shares would be purchased at 96.0% of the average of the daily volume weighted average price of the Company’s common stock as reported by Bloomberg L.P. during regular trading hours during each of the three consecutive trading days commencing on the trading day following the Company’s submission of an Advance notice to Yorkville and would be subject to certain limitations, including that Yorkville could not purchase any shares that would result in it owning more than 4.99% of the Company’s outstanding common stock at the time of an Advance. On July 11, 2022, the Company filed a Form S-1 registration statement registering up to 30,000,000 shares of common stock underlying the SEPA. The registration statement was declared effective on July 19, 2022. During the three months ended March 31, 2023, the Company made one Advance under the SEPA, receiving $18,765 in proceeds for the issuance of 225,000 shares of common stock, all of which was applied to the balance of the Yorkville Promissory Note that was repaid in first quarter 2023. No Advances were made during the three months ended March 31, 2024. Private Placements During the three months ended March 31, 2024, the Company sold 5,100,000 shares of common stock to three investors in separate private placement transactions. The Company received $355,000 in proceeds from the sales. In connection with the stock sales, the Company also issued 2,500,000 five-year warrants to purchase shares of common stock at an exercise price of $0.17 per share. During the three months ended March 31, 2023, the Company sold 2,000,000 shares of common stock to one investor in a private placement transaction. The Company received $200,000 in proceeds from the sale. In connection with the stock sale, the Company also issued 1,500,000 five-year warrants to purchase shares of common stock at an exercise price of $0.20 per share. Shares issued to Consultants During the three months ended March 31, 2024, the Company issued to a consultant a ten-year stock option to purchase 2,504,974 shares of common stock at an exercise price equal of $0.0569 in satisfaction of common stock issuable accrued to the consultant for services provided between 2021 and 2024. Common Stock Issuable As of March 31, 2024 and December 31, 2023, the Company was obligated to issue the following shares: March 31, 2024 December 31, 2023 Amount Shares Amount Shares Shares issuable to employees and consultants $ 14,570 239,208 $ 261,682 2,356,188 Shares issuable to independent directors 40,000 816,328 20,000 408,164 $ 54,570 1,055,536 $ 281,682 2,764,352 Stock Warrants Transactions involving our stock warrants during the three months ended March 31, 2024 and 2023 are summarized as follows: 2024 2023 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 77,414,648 $ 0.20 68,109,094 $ 0.23 Granted during the period 9,160,000 $ 0.09 3,141,554 $ 0.15 Exercised during the period --- $ --- --- $ --- Expired during the period (1,217,402 ) $ (0.28 ) (2,508,333 ) $ (0.25 ) Outstanding at end of the period 85,357,246 $ 0.19 68,742,315 $ 0.22 Exercisable at end of the period 85,357,246 $ 0.19 68,742,315 $ 0.22 Weighted average remaining life 2.7 years 2.5 years The following table summarizes information about the Company’s stock warrants outstanding as of March 31, 2024: Warrants Outstanding Warrants Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.0001 to 0.09 29,968,289 3.6 $ 0.07 29,968,289 $ 0.07 $ 0.10 to 0.24 25,436,940 3.0 $ 0.16 25,436,940 $ 0.16 $ 0.25 to 0.49 26,992,093 1.5 $ 0.31 26,992,093 $ 0.31 $ 0.50 to 1.05 2,959,924 2.3 $ 0.68 2,959,924 $ 0.68 $ 0.05 to 1.00 85,357,246 2.7 $ 0.19 85,357,246 $ 0.19 During the three months ended March 31, 2024 and 2023, the Company issued 9,160,000 and 3,141,554 warrants, respectively, the aggregate grant date fair value of which was $385,633 and $246,063, respectively. The fair value of the warrants was calculated using the following range of assumptions: 2024 2023 Pricing model utilized Binomial Lattice Binomial Lattice Risk free rate range 3.97% to 4.20% 3.45% to 5.43% Expected life range (in years) 5.00 years to 10.00 years 0.28 years to 5.00 years Volatility range 140.94% to 173.25% 126.30% to 165.20% Dividend yield 0.00% 0.00% Expected forfeiture 33.00% 20.00% There were no warrants exercised during the three months ended March 31, 2024 or 2023. Equity Incentive Plans On January 1, 2016, the Company adopted the 2016 Equity Incentive Plan (the “2016 EIP”) for the purpose of having equity awards available to allow for equity participation by its employees, consultants and non-employee directors. The 2016 EIP allowed for the issuance of up to 15,503,680 shares of the Company’s common stock, which may be issued in the form of stock options, stock appreciation rights, or common shares. The 2016 EIP is governed by the Board, or a committee that may be appointed by the Board in the future. The 2016 EIP expired during 2021 but allows for the prospective issuance of common shares upon vesting of stock awards or exercise of stock options granted prior to expiration of the 2016 EIP. On September 9, 2021, the Company adopted the 2021 Equity Incentive Plan (the “2021 EIP” and, together with the 2016 EIP, the “EIPs”) for the purpose of having equity awards available to allow for equity participation by its employees, consultants and non-employee directors. The 2021 EIP allows for the issuance of up to 20,000,000 shares of the Company’s common stock, which may be issued in the form of stock options, stock appreciation rights, or common shares. The 2021 EIP is governed by the Board, or a committee that may be appointed by the Board in the future. Amounts recognized in the financial statements with respect to the EIPs in the three months ended March 31, 2024 and 2023 were as follows: Three Months Ended 2024 2023 Total cost of share-based payment plans during the period $ 35,986 $ 82,951 Amounts capitalized in deferred equity compensation during period $ --- $ --- Amounts written off from deferred equity compensation during period $ 57,147 $ --- Amounts charged against income for amounts previously capitalized $ --- $ 5,150 Amounts charged against income, before income tax benefit $ 93,133 $ 88,101 Amount of related income tax benefit recognized in income $ --- $ --- Stock Options Stock options granted under the EIPs typically vest over a period of three to four years or based on achievement of Company and individual performance goals. The following table summarizes stock option activity as of and for the three months ended March 31, 2024 and 2023: 2024 2023 Weighted Weighted Average Average Exercise Exercise Stock options Number Price Number Price Outstanding at beginning of period 5,093,738 $ 0.16 5,222,982 $ 0.20 Granted during the period 4,504,974 $ 0.06 93,750 $ 0.08 Exercised during the period --- $ --- --- $ --- Forfeited during the period (449,982 ) $ (0.21 ) (150,000 ) $ (0.16 ) Outstanding at end of period 9,148,730 $ 0.10 5,166,732 $ 0.17 Options exercisable at period-end 7,063,146 $ 0.11 3,108,565 $ (0.20 ) As of March 31, 2024, there was $78,222 of total unrecognized compensation cost related to options granted under the EIPs. That cost is expected to be recognized over a weighted-average period of 1.7 years. The weighted-average grant-date fair value of options granted during the three months ended March 31, 2024 and 2023 was $0.04 and $0.05, respectively. The total fair value of options vested during the three months ended March 31, 2024 and 2023 was $137,040 and $26,845, respectively. No options were exercised during the three months ended March 31, 2024 or 2023. Stock based compensation expense related to stock options was $47,900 and $22,511 in the three months ended March 31, 2024 and 2023, respectively. The fair value of each stock option award is estimated on the date of grant using a binomial lattice option-pricing model based on the assumptions noted in the following table. The Company’s accounting policy is to estimate forfeitures in determining the amount of total compensation cost to record each period. The fair value of options granted for the three months ended March 31, 2024 and 2023 was calculated using the following range of assumptions: 2024 2023 Pricing model utilized Binomial Lattice Binomial Lattice Risk free rate range 4.20% 3.48% Expected life range (in years) 10.00 years 10.00 years Volatility range 173.25% 145.03% Dividend yield 0.00% 0.00% Expected forfeiture 30.00% 30.00% The following table summarizes the status and activity of nonvested options issued pursuant to the EIPs as of and for the three months ended March 31, 2024 and 2023: 2024 2023 Weighted Weighted Average Average Grant Date Grant Date Stock options Shares Fair Value Shares Fair Value Nonvested options at beginning of period 1,073,084 $ 0.06 2,260,417 $ 0.08 Granted 4,504,974 $ 0.04 93,750 $ 0.05 Vested (3,442,474 ) $ (0.04 ) (196,000 ) $ (0.14 ) Forfeited (50,000 ) $ (0.08 ) (100,000 ) $ (0.09 ) Nonvested options at end of period 2,085,584 $ 0.05 2,058,167 $ 0.07 Stock Grants Stock grant awards made under the EIPs typically vest either immediately or over a period of up to four years. The following table summarizes stock grant activity as of and for the three months ended March 31, 2024 and 2023: 2024 2023 Weighted Weighted Average Average Grant Date Grant Date Stock Grants Shares Fair Value Shares Fair Value Nonvested grants at beginning of period 1,484,488 $ 0.05 1,651,435 $ 0.05 Granted --- $ --- 160,944 $ 0.09 Vested (408,164 ) $ (0.05 ) (468,292 ) $ (0.05 ) Forfeited (50,000 ) $ (0.12 ) --- $ --- Nonvested grants at end of period 1,026,324 $ 0.05 1,344,087 $ 0.06 As of March 31, 2024, there was $10,449 of total unrecognized compensation cost related to stock grants made under the EIPs. That cost is expected to be recognized over a weighted-average period of 1.5 years. The weighted-average grant-date fair value of share grants made during the three months ended March 31, 2023 was $0.09 per share. No grants were made in the three months ended March 31, 2024. The aggregate fair value of share grants that vested during the three months ended March 31, 2024 and 2023 was $20,000 and $22,460, respectively. Stock based compensation expense related to stock grants was $1,796 and $25,467 in the three months ended March 31, 2024 and 2023, respectively. The fair value of each stock grant is calculated using the closing sale price of the Company’s common stock on the date of grant. The Company’s accounting policy is to estimate forfeitures in determining the amount of total compensation cost to record each period. Liability-Classified Equity Instruments During 2021, the Company made certain stock grants from the 2021 EIP that vest over a four-year period and that are settleable for a fixed dollar amount rather than a fixed number of shares. During 2022, the Company made an additional grant of stock options from the 2021 EIP with a fixed fair value that may be earned based on achievement of performance targets on a quarterly basis through June 2025. The Company recognized an asset captioned “Deferred equity compensation” and an offsetting liability captioned as a “Liability-classified equity instrument” related to such instruments. Amortization of deferred stock compensation assets in the three months ended March 31, 2024 and 2023 was $-0- and $5,150, respectively. The liability will be converted to equity if and when shares are earned and issued pursuant to prescribed vesting events. The Company subsequently de-recognized Deferred equity compensation and Liability-classified equity instruments upon termination of the instruments in 2022 and 2023 and no further equity-related assets or liabilities remained as of March 31, 2024.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 14 – COMMITMENTS AND CONTINGENCIES Supplier Concentration The Company relied on a single supplier for the fulfillment of approximately 91% and 95% of its product sales made through MOD in the three months ended March 31, 2024 and 2023, respectively. Service Contracts The Company carries various service contracts on its office buildings and certain copier equipment for repairs, maintenance and inspections. All contracts are short term and can be cancelled. Leases Maturities of operating lease liabilities were as follows as of March 31, 2024: 2024 $ 390,027 2025 467,994 2026 335,634 2027 990 Total lease payments 1,194,645 Less interest (337,407 ) Present value of lease liabilities $ 857,238 Employment/Consulting Agreements The Company has employment agreements with certain of its physicians, nurse practitioners and physical therapists in the Health Services Division. The agreements generally call for a fixed salary plus performance-based pay. On March 1, 2024, the Company entered into an offer letter agreement with David Rosal, Chief Financial Officer of the Company. The agreement was effective as of March 11, 2024 and provides that Mr. Rosal’s base salary will be $150,000 per year. Mr. Rosal is eligible to receive grants from the Company’s Employee Stock Option Plan. Mr. Rosal’s employment is at-will with no defined contractual employment period. On July 1, 2016, the Company entered into an employment agreement with Dr. Michael Dent, Chief Executive Officer and a member of the Board of Directors. Dr. Dent’s employment agreement continues until terminated by Dr. Dent or the Company. If Dr. Dent’s employment is terminated by the Company (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Dr. Dent will be entitled to severance in an amount equal to 12 months of his then-current annual base salary, as well as the pro-rata portion of any bonus that would be due and payable to him. In the event that Dr. Dent terminates the employment agreement, he shall be entitled to any accrued but unpaid salary and other benefits up to and including the date of termination, and the pro-rata portion of any unvested time-based options up until the date of termination. Litigation From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. The Company is not aware of any such legal proceedings that will have, individually or in the aggregate, a material adverse effect on its business, financial condition or operating results.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 15 – SEGMENT REPORTING As of March 31, 2024, the Company had three reportable segments: Health Services, Digital Healthcare, and Medical Distribution. The Health Services Division is comprised of the operations of (i) NWC, a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology), and General Practice, (ii) NCFM, a Functional Medical Practice acquired in April 2019 that is engaged in improving the health of its patients through individualized and integrative health care, (iii) BTG, a physical therapy practice in Bonita Springs, Florida that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery, and (iv) AEU, a patient service facility specializing in minimally and non-invasive cosmetic services acquired by the Company in May 2022. The Digital Healthcare segment develops and plans to operate an online personal medical information and record archive system, the “HealthLynked Network,” which will enable patients and doctors to keep track of medical information via the Internet in a cloud-based system. The Medical Distribution Division is comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States. On January 17, 2023, the Company entered into the AHP Merger Agreement pursuant to which the Company sold AHP and discontinued the operations of CHM, comprising its ACO/MSO Division. The Company has classified the results of the ACO/MSO Division as discontinued operations in the accompanying consolidated statement of operations for all periods presented. See Note 4, “Discontinued Operations,” for additional information. The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. Segment information for the year ended three months ended March 31, 2024 was as follows: Three Months ended March 31, 2024 Health Services Digital Healthcare Medical Distribution Total Revenue Patient service revenue, net $ 963,621 $ --- $ --- $ 963,621 Subscription revenue --- 7,628 --- 7,628 Product and other revenue --- --- 32,983 32,983 Total revenue 963,621 7,628 32,983 1,004,232 Operating Expenses Practice salaries and benefits 583,156 --- --- 583,156 Other practice operating expenses 482,583 --- --- 482,583 Cost of product revenue --- --- 30,579 30,579 Selling, general and administrative expenses --- 980,174 19,269 999,443 Depreciation and amortization 85,169 1,340 --- 86,509 Total Operating Expenses 1,150,908 981,514 49,848 2,182,270 Income (loss) from operations $ (187,287 ) $ (973,886 ) $ (16,865 ) $ (1,178,038 ) Other Segment Information Loss on extinguishment of debt $ --- $ 96,660 $ --- $ 96,660 Amortization of original issue discounts on notes payable $ 108,265 $ --- $ --- $ 108,265 Change in fair value of contingent acquisition consideration $ --- $ (76 ) $ --- $ (76 ) Interest expense $ 3,881 $ 950 $ --- $ 4,831 Identifiable Assets Identifiable assets as of March 31, 2024 $ 1,635,387 $ 2,246,600 $ 8,772 $ 3,890,759 Identifiable assets as of December 31, 2023 $ 1,812,609 $ 2,457,849 $ 9,682 $ 4,280,140 Segment information for the three months ended three months ended March 31, 2023 was as follows: Three Months Ended March 31, 2023 Health Services Digital Healthcare Medical Distribution Total Revenue Patient service revenue, net $ 1,700,281 $ --- $ --- $ 1,700,281 Subscription revenue --- 16,299 --- 16,299 Product and other revenue --- --- 38,574 38,574 Total revenue 1,700,281 16,299 38,574 1,755,154 Operating Expenses Practice salaries and benefits 963,657 --- --- 963,657 Other practice operating expenses 624,247 --- --- 624,247 Cost of product revenue --- --- 32,060 32,060 Selling, general and administrative expenses --- 1,070,321 33,427 1,103,748 Depreciation and amortization 86,672 1,405 --- 88,077 Total Operating Expenses 1,674,576 1,071,726 65,487 2,811,789 Income (loss) from operations $ 25,705 $ (1,055,427 ) $ (26,913 ) $ (1,056,635 ) Other Segment Information Interest expense (income) $ --- $ 44,763 $ --- $ 44,763 Financing cost $ 2,812 $ 8,569 $ --- $ 11,381 Amortization of original issue discounts on notes payable $ 60,993 $ 2,367 $ --- $ 63,360 Change in fair value of contingent acquisition consideration $ --- $ 1,706 $ --- $ 1,706 Identifiable Assets Identifiable assets as of March 31, 2023 $ 2,204,934 $ 3,606,105 $ 14,203 $ 5,825,242 Goodwill as of March 31, 2023 $ 319,958 $ --- $ --- $ 319,958 The Digital Healthcare Division made intercompany sales of $180 and $180 in the three months ended March 31, 2024 and 2023, respectively, related to subscription revenue billed to and paid for by the Company’s physicians for access to the HealthLynked Network. The Medical Distribution segment made intercompany sales of $-0- and $8,340 in the three months ended March 31, 2024 and 2023, respectively, related to medical products sold to practices in the Company’s Health Services segment. Intercompany revenue and the related costs are eliminated on consolidation.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2024
Fair Value of Financial Instruments [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	NOTE 16 – FAIR VALUE OF FINANCIAL INSTRUMENTS The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate their respective fair values due to the short-term nature of such instruments. The Company measures certain financial instruments at fair value on a recurring basis, including certain convertible notes payable and related party loans, which were extinguished and reissued and are therefore subject to fair value measurement, derivative financial instruments arising from conversion features embedded in convertible promissory notes for which the conversion rate was not fixed, and equity-class. All financial instruments carried at fair value fall within Level 3 of the fair value hierarchy as their value is based on unobservable inputs. The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of March 31, 2024 and December 31, 2023: As of March 31, 2024 As of December 31, 2023 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Contingent sale consideration receivable $ --- $ --- $ 1,663,163 $ 1,663,163 $ --- $ --- $ 1,663,163 $ 1,663,163 Liabilities: Contingent acquisition consideration payable --- --- 2,113 2,113 --- --- 2,189 2,189 Convertible note payable to related party --- --- 199,621 199,621 --- --- --- --- $ --- $ --- $ 201,734 $ 201,734 $ --- $ --- $ 2,189 $ 2,189 Contingent acquisition consideration payable is a Level 3 financial instrument that is measured at fair value on a recurring basis. Gains (losses) from the change in fair value of contingent acquisition consideration payable were $76 and ($1,706) during the three months ended March 31, 2024 and 2023, respectively.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 17 – SUBSEQUENT EVENTS On April 10, 2024, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $150,000, an interest rate of 12% per annum, and a maturity date of October 10, 2024. The convertible note payable is convertible at any time at the holder’s option into shares of the Company common stock at a fixed conversion price of $0.0577 per share. On April 12, 2024, the Company sold 877,193 shares of common stock for cash in a private placement transaction to an accredited investor. The Company received $50,000 in proceeds from the sale. In connection with the stock sale, the Company also issued 438,596 five-year warrants to purchase shares of common stock at an exercise price of $0.16 per share. On April 18, 2024, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $50,000, an interest rate of 12% per annum, and a maturity date of October 18, 2024. The convertible note payable is convertible at any time at the holder’s option into shares of the Company common stock at a fixed conversion price of $0.05 per share. On April 22, 2024, the Company issued a promissory note payable to an investor with a stated principal amount of $161,000 and prepaid interest of $19,320 for total repayments of $180,320. The Company received net proceeds of $118,787 after original issue discount of $21,000, fees of $5,000, and withholding of the final payment due on the August 2023 Note to the same investor in the amount of $16,213. The note does not bear interest in excess of the original issue discount and prepaid interest and matures on February 28, 2025. The Company is required to make 10 monthly payments of $18,032 starting May 30, 2024 and ending on February 28, 2025. The note gives the holder a conversion right at a 15% discount to the market price of the Company’s common stock in the event of default. On May 6 and May 8, 2024, a trust controlled by Dr. Michael Dent advanced $100,000 and $70,000, respectively, to the Company. The advances are expected to be documented in formal debt agreements in the second quarter of 2024.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (1,387,718)	$ 1,451,935

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2024
Business and Business Presentation [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP. All amounts referred to in the notes to the condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about fair valuation of acquired intangible assets; cash flow and fair value assumptions associated with measurements of contingent sale consideration receivable, contingent acquisition consideration payable, and impairment of intangible assets; valuation of inventory; collection of accounts receivable; the valuation and recognition of stock-based compensation expense; valuation allowance for deferred tax assets; and borrowing rate consideration for right-of-use (“ROU”) lease assets including related lease liability and useful life of fixed assets.
Revenue Recognition	Revenue Recognition Patient service revenue Patient service revenue is earned for patient services provided to patients at our NWC facility, functional medicine services provided to patients at our NCFM facility, and physical therapy services provided to patients at our BTG facility. Patient service revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients and third-party payors (including health insurers and government programs) and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Company bills patients and third-party payors within days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time includes revenue from NCFM annual access contracts (called the Medical Membership and Concierge Program prior to October 1, 2023 and Optimal Health 365 Access Plan thereafter), NWC annual administration fees, and BTG physical therapy bundles. Revenue from NCFM Medical Memberships and Concierge contracts and NWC annual administration fees, which include bundled products and services that have substantially the same pattern of transfer to the customer, is recognized over the period of delivery, which is the same as the period of the contract (typically, one year). Revenue from prepaid BTG physical therapy bundles, for which performance obligations are satisfied over time as visits are incurred, is recognized based on actual visits incurred in relation to total expected visits. At inception of such contracts, the Company recognizes contract liabilities for the value of services to be provided and, where applicable, contract assets for recoverable amounts incurred to obtain a customer contract that would not have incurred if the contract had not been obtained. The Company believes that these methods provide a faithful depiction of the transfer of services over the term of the performance obligations based on the inputs needed to satisfy the obligation. Revenue for performance obligations satisfied at a point in time, which includes all patient service revenue other than NCFM annual access contracts, NWC annual administration fees, and BTG physical therapy bundles, is recognized when goods or services are provided at the time of the patient visit, and at which time the Company is not required to provide additional goods or services to the patient. The Company determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. Estimates of contractual adjustments and discounts require significant judgment and are based on the Company’s current contractual agreements, its discount policies, and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. There were no material changes during the three months ended March 31, 2024 or 2023 to the judgments applied in determining the amount and timing of patient service revenue. Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows: ● Medicare: Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates; ● Medicaid: Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member. ● Other: Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates. Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Company estimates the transaction price for patients with deductibles and coinsurance and for those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Patient services provided by NCFM, BTG and AEU are provided on a cash basis and not submitted through third party insurance providers. Product and Other Revenue Revenue is derived from the distribution of medical products that are sourced from a third party. The Company recognizes revenue at a point in time when title transfers to customers and the Company has no further obligation to provide services related to such products, which occurs when the product ships. The Company is the principal in its revenue transactions and as a result revenue is recorded on a gross basis. The Company has determined that it controls the ability to direct the use of the product provided prior to transfer to a customer, is primarily responsible for fulfilling the promise to provide the product to its customer, has discretion in establishing prices, and ultimately controls the transfer of the product to the customer. Shipping and handling costs billed to customers are recorded in revenue. Contract liabilities related to product revenue are recognized when payment is received but for which the Company has not met its product fulfillment performance obligation. Sales are made inclusive of sales tax, where such sales tax is applicable. Sales tax is applicable on sales made in the state of Florida, where the Company has physical nexus. The Company has determined that it does not have economic nexus in any other states. The Company does not sell products outside of the United States. The Company maintains a return policy that allows customers to return a product within a specified period of time prior to and subsequent to the expiration date of the product. The Company analyzes the need for a product return allowance at the end of each period based on eligible products.
Cash and Cash Equivalents	Cash and Cash Equivalents For financial statement purposes, the Company considers all highly liquid investments with original maturities of six months or less to be cash and cash equivalents. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company had $-0- and $-0- in cash balances in excess of the FDIC insured limit as of March 31, 2024 and December 31, 2023, respectively.
Accounts Receivable	Accounts Receivable Trade receivables related to NWC services billed to third party payors are carried at the estimated collectible amount. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates 61% of total billings. Trade accounts receivable are recorded at this net amount. As of March 31, 2024 and December 31, 2023, the Company’s gross patient services accounts receivable were $40,295 and $34,481, respectively, and net patient services accounts receivable were $33,620 and $20,861, respectively, based upon net reporting of accounts receivable. As of March 31, 2024 and December 31, 2023, the Company’s allowance for doubtful accounts was $-0- and $-0-, respectively.
Other Comprehensive Income	Other Comprehensive Income The Company does not have any activity that results in Other Comprehensive Income.
Leases	Leases Upon transition under ASU 2016-02, the Company elected the suite of practical expedients as a package applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. For new leases, the Company will determine if an arrangement is or contains a lease at inception. Leases are included as ROU assets within other assets and ROU liabilities within accrued expenses and other liabilities and within other long-term liabilities on the Company’s consolidated balance sheets. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s leases do not provide an implicit rate. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. See Note 8 for more complete details on balances as of the reporting periods presented herein.
Inventory	Inventory Inventory consisting of supplements, is stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method. Outdated inventory is directly charged to cost of goods sold.
Intangible Assets	Intangible Assets The Company recognizes an acquired intangible whenever the intangible arises from contractual or other legal rights, or whenever it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their estimated useful lives unless the estimated useful life is determined to be indefinite. Amortizable intangible assets are being amortized primarily over useful lives of five years. The straight-line method of amortization is used as it has been determined to approximate the use pattern of the assets. Impairment losses are recognized if the carrying amount of an intangible that is subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. The Company relies on a sole supplier for the fulfillment of substantially all of its product sales made through MOD.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.
Fair Value of Assets and Liabilities	Fair Value of Assets and Liabilities Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs: ● Level 1 – Fair value based on quoted prices in active markets for identical assets or liabilities; ● Level 2 – Fair value based on significant directly observable data (other than Level 1 quoted prices) or significant indirectly observable data through corroboration with observable market data. Inputs would normally be (i) quoted prices in active markets for similar assets or liabilities, (ii) quoted prices in inactive markets for identical or similar assets or liabilities or (iii) information derived from or corroborated by observable market data; ● Level 3 – Fair value based on prices or valuation techniques that require significant unobservable data inputs. Inputs would normally be a reporting entity’s own data and judgments about assumptions that market participants would use in pricing the asset or liability. The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a binomial lattice option pricing model to estimate the fair value of options, warrants, beneficial conversion features and other Level 3 financial assets and liabilities. The Company believes that the binomial lattice model results in the best estimate of fair value because it embodies all of the requisite assumptions (including the underlying price, exercise price, term, volatility, and risk-free interest-rate) necessary to fairly value these instruments and, unlike less sophisticated models like the Black-Scholes model, it also accommodates assumptions regarding investor exercise behavior and other market conditions that market participants would likely consider in negotiating the transfer of such an instruments.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation to employees and nonemployees under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718 “Compensation – Stock Compensation” using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company uses a binomial lattice pricing model to estimate the fair value of options and warrants granted.
Income Taxes	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. No income tax has been provided for the three months ended March 31, 2024 since the Company sustained a loss in that period. No income tax was provided for the three months ended March 31, 2023 because the Company had sufficient operating loss carryforwards to offset any net income for the full year 2023, including income from capital gains related to the disposal of discontinued operations. The Company recognized net loss for the full year 2023. Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, management has determined a full valuation allowance for the deferred tax assets, since it is more likely than not that the deferred tax assets will not be realizable.
Recurring Fair Value Measurements	Recurring Fair Value Measurements The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, accounts payable, and accrued liabilities approximated their fair value.
Net Income (Loss) per Share	Net Income (Loss) per Share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the three months ended March 31, 2024 and 2023, the Company reported a loss from continuing operations. As a result, diluted net income (loss) per common share is computed in the same manner as basic net income (loss) per common share, even though the Company had net income in the three months ended March 31, 2023 after adjusting for discontinued operations. The Company excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of March 31, 2024 and December 31, 2023, potentially dilutive securities were comprised of (i) 85,357,246 and 77,414,648 warrants outstanding, respectively, (ii) 7,063,146 and 5,093,738 stock options outstanding, respectively, (iii) 1,026,324 and 1,484,488 unissued shares subject to future vesting requirements granted pursuant to the Company’s Employee Incentive Plan, (iv) up to 1,055,536 and 2,764,352 common shares issuable that are earned but not paid under consulting and director compensation arrangements, and (v) up to 13,750,000 and 13,750,000 shares of common stock issuable upon conversion of Series B Preferred.
Common Stock Awards	Common Stock Awards The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded on the consolidated statement of operations in the same manner and charged to the same account as if such settlements had been made in cash. From time to time, the Company also issues stock awards settleable in a variable number of common shares. Such awards are classified as liabilities until such time as the number of shares underlying the grant is determinable.
Warrants	Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes pricing model as of the measurement date. The Company uses a binomial lattice pricing model to estimate the fair value of compensation options and warrants. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period, or at the date of issuance, if there is not a service period. Certain of the Company’s warrants include a so-called down round provision. The Company accounts for such provisions pursuant to ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging
Business Segments	Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has three operating segments: Health Services (multi-specialty medical group including the NWC GYN practice, the NCFM functional medicine practice, the BTG physical therapy practice, and the AEU cosmetic services practice), Digital Healthcare (develops and markets the “HealthLynked Network,” an online personal medical information and record archive system), and Medical Distribution (comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices). The Company’s ACO/MSO segment was sold on January 17, 2023. As described in further detail in Note 4, “Discontinued Operations,” this unit’s assets and liabilities are classified as held for sale as of December 31, 2022 and the unit’s results of operations are classified as “Income (loss) from operations of discontinued operations” in the three months ended March 31, 2024 and 2023.
Recently Adopted Pronouncements	Recently Adopted Pronouncements In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments.” The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. The Company adopted this standard for the year ended December 31, 2023. The adoption did not have a material effect on the Company’s consolidated financial statements. In October 2021, the FASB issued guidance which requires companies to apply Topic 606, Revenue from Contracts with Customers In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard in the three months ended March 31, 2024. The adoption did not have a material effect on the Company’s consolidated financial statements. In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard in the three months ended March 31, 2024. The adoption did not have a material effect on the Company’s consolidated financial statements. No other new accounting pronouncements were issued or became effective in the period that had, or are expected to have, a material impact on our consolidated Financial Statements.

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2024
Discontinued Operations [Abstract]
Schedule of Financial Results of the ACO/MSO Division	The following table presents financial results of the ACO/MSO Division for the three months ended March 31, 2024: Three Months Ended 2024 2023 Revenue: Consulting revenue $ --- $ 23,646 Total revenue --- 23,646 Operating Expenses and Costs: Medicare shared savings expenses --- 67,935 Loss from operations of discontinued operations before income taxes --- (44,289 ) Provision for income taxes --- --- Loss from discontinued operations, net of income taxes $ --- $ (44,289 )
Schedule of Fair Value of Consideration Received and Receivable	The fair value of consideration received and receivable is shown in the following table: Upfront Cash Consideration paid at signing $ 750,000 Incremental Cash Consideration 1,311,567 IPO Share Consideration 1,463,517 2022 MSSP Consideration 312,987 Physician Advance Consideration 199,645 Stub Period Reimbursement 31,381 Total fair value of contingent consideration receivable 3,319,097 Total fair value of consideration received and receivable $ 4,069,097
Schedule of Assets and Liabilities Derecognized	The book value of the assets and liabilities derecognized on January 17, 2023 in connection with the sale were as follows: Prepaid expenses $ 1,500 Intangible asset - ACO physician contract 1,073,000 Goodwill 381,856 Contract liability (20,278 ) Contingent acquisition consideration (185,024 ) Net Book Value of Assets and Liabilities Sold $ 1,251,054
Schedule of Fair Value of Consideration and Derecognition of Assets and Liabilities	After recording the fair value of consideration and derecognition of assets and liabilities, and an estimated liability related to the Indemnification Clause, the Company recorded a gain from disposal of discontinued operations in the amount of $2,674,069 in the three months ended Mach 31, 2023 as follows: Total fair value of consideration received and receivable $ 4,069,097 Less: net book value of assets and liabilities sold (1,251,054 ) Less: fair value of Indemnification Clause (143,974 ) Gain from disposal of discontinued operations $ 2,674,069
Schedule of Remaining Unresolved of Contingent Consideration Receivable	The carrying value of the remaining unresolved components of contingent consideration receivable as of March 31, 2024 and December 31, 2023 was as follows: IPO Share Consideration $ 1,463,518 Physician Advance Consideration 199,645 Remaining contingent sale consideration receivable $ 1,663,163

Prepaid Expenses and Other (Tab

Prepaid Expenses and Other (Tables)	3 Months Ended
	Mar. 31, 2024
Prepaid Expenses and Other [Abstract]
Schedule of Prepaid and Other Expenses	Prepaid and other expenses as of March 31, 2024 and December 31, 2023 were as follows: March 31, December 31, 2024 2023 Insurance prepayments $ 7,791 $ 11,209 Other expense prepayments 22,475 38,391 Rent deposits 50,047 50,547 Contract assets 9,750 5,110 Total prepaid expenses and other 90,063 105,257 Less: long term portion (50,047 ) (50,047 ) Prepaid expenses and other, current portion $ 40,016 $ 55,210

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property and equipment as of March 31, 2024 and December 31, 2023 were as follows: March 31, December 31, 2024 2023 Medical equipment $ 496,452 $ 493,854 Furniture, office equipment and leasehold improvements 317,963 317,963 Total property and equipment 814,415 811,817 Less: accumulated depreciation (550,531 ) (521,062 ) Property and equipment, net $ 263,884 $ 290,755

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Intangible Assets and Goodwill [Abstract]
Schedule of Intangible Assets	Identifiable intangible assets as of March 31, 2024 and December 31, 2023 were as follows: March 31, December 31, 2024 2023 NCFM: Medical database $ 1,101,538 $ 1,101,538 NCFM: Website 41,000 41,000 Total intangible assets 1,142,538 1,142,538 Less: accumulated amortization (315,730 ) (258,690 ) Intangible assets, net $ 826,808 $ 883,848
Schedule of Future Amortization Expense of Intangible Assets	Future amortization expense of intangible assets is expected to be as follows: 2024 (April to December) $ 165,885 2025 220,308 2026 220,308 2027 220,307 Thereafter --- Total future amortization expense $ 826,808

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Schedule of Lease-Related Assets and Liabilities	The table below summarizes the Company’s lease-related assets and liabilities as of March 31, 2024 and December 31, 2023: March 31, December 31, 2024 2023 Lease assets $ 853,525 $ 935,812 Lease liabilities Lease liabilities (short term) $ 332,692 $ 326,033 Lease liabilities (long term) 524,546 613,386 Total lease liabilities $ 857,238 $ 939,419
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities were as follows as of March 31, 2024: 2024 $ 390,027 2025 467,994 2026 335,634 2027 990 Total lease payments 1,194,645 Less interest (337,407 ) Present value of lease liabilities $ 857,238

Accounts Payable, Accrued Exp_2

Accounts Payable, Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Accounts Payable and Accrued Expenses [Abstract]
Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities	Amounts related to accounts payable, accrued expenses and other current liabilities as of March 31, 2024 and December 31, 2023 were as follows: March 31, December 31, 2024 2023 Trade accounts payable $ 372,612 $ 251,479 Accrued payroll liabilities 76,646 110,103 Accrued operating expenses 175,349 91,238 Accrued interest 52,287 57,074 Accrued commissions payable from 2022 MSSP Consideration (a) 25,000 100,000 Contingent acquisition consideration payable (b) 2,113 2,189 Product return allowance 1,117 2,095 $ 705,124 $ 614,178 (a) During September 2023, AHP received from the CMS a final determination of AHP’s Plan Year 2022 MSSP shared savings, of which the Company realized gross receipts of $1,873,993 and net proceeds of $1,186,231 after payments to participating physicians and commissions in satisfaction of the 2022 MSSP Consideration. Gross payment was received by the Company in October 2023. As of December 31, 2023, the Company’s remaining accrued commissions and other fees payable resulting from the receipt and prior consideration received in the amount of $100,000, of which $75,000 was paid in the three months ended March 31, 2024. See Note 4 for complete description of the AHP Sale and related consideration. (b) Contingent acquisition consideration reflects the fair value of the final earn-out payment potentially payable related to the Company’s acquisitions of MOD in 2020. All of the remaining $2,113 contingent acquisition consideration related to MOD matures in 2024 based on the performance of the business unit for the year ended December 31, 2024.

Contract Liabilities (Tables)

Contract Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Contract Assets and Liabilities [Abstract]
Schedule of Amounts Related to Contract Liabilities	Amounts related to contract liabilities as of March 31, 2024 and December 31, 2023 were as follows: March 31, December 31, 2024 2023 Patient services paid but not provided - NCFM $ 175,333 $ 95,334 Patient services paid but not provided - BTG 90,599 100,857 Patient services paid but not provided - NWC 64,114 75,438 Unshipped products - MOD 1,394 145 $ 331,440 $ 271,774

Amounts Due to Related Party _2

Amounts Due to Related Party and Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2024
Amounts Due to Related Party and Related Party Transactions [Abstract]
Schedule of Amounts Due to Related Parties	Amounts due to related parties as of March 31, 2024 and December 31, 2023 were comprised of the following: March 31, December 31, 2024 2023 Note Payable to Dr. Michael Dent, March 2023 $ --- $ 12,601 Note Payable to Dr. Michael Dent, June 2023 --- 26,875 Note Payable to Dr. Michael Dent, December 2023 --- 166,500 Convertible Note Payable I to Dr. Michael Dent, March 2024 150,000 --- Convertible Note Payable II to Dr. Michael Dent, March 2024 350,000 --- Convertible Note Payable III to Dr. Michael Dent, March 2024 199,621 --- Face value of notes payable to related party 699,621 205,976 Less: unamortized discounts (281,579 ) (34,834 ) Notes payable to related party, total 418,042 171,142 Plus deferred compensation payable to Dr. Michael Dent 300,600 300,600 Total due to related party $ 718,642 $ 471,742

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Payable [Abstract]
Schedule of Notes Payable	Notes payable as of March 31, 2024 and December 31, 2023 were as follows: March 31, December 31, 2024 2023 SBA Disaster Relief Loans $ 450,000 $ 450,000 1800 Diagonal Note Payable III, August 2023 64,853 97,279 Yorkville Note Payable III, November 2023 226,800 302,400 1800 Diagonal Note Payable III, December 2023 113,482 162,131 Yorkville Note Payable III, December 2023 162,000 189,000 Face value of notes payable 1,017,135 1,200,810 Less: unamortized discounts (104,288 ) (166,487 ) Notes payable, total 912,847 1,034,323 Less: long term portion (450,000 ) (450,000 ) Notes payable, current portion $ 462,847 $ 584,323

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2024
Shareholders' Equity (Tables) [Line Items]
Schedule of Company Obligated to Issue Shares	As of March 31, 2024 and December 31, 2023, the Company was obligated to issue the following shares: March 31, 2024 December 31, 2023 Amount Shares Amount Shares Shares issuable to employees and consultants $ 14,570 239,208 $ 261,682 2,356,188 Shares issuable to independent directors 40,000 816,328 20,000 408,164 $ 54,570 1,055,536 $ 281,682 2,764,352
Schedule of Stock Warrants	Transactions involving our stock warrants during the three months ended March 31, 2024 and 2023 are summarized as follows: 2024 2023 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 77,414,648 $ 0.20 68,109,094 $ 0.23 Granted during the period 9,160,000 $ 0.09 3,141,554 $ 0.15 Exercised during the period --- $ --- --- $ --- Expired during the period (1,217,402 ) $ (0.28 ) (2,508,333 ) $ (0.25 ) Outstanding at end of the period 85,357,246 $ 0.19 68,742,315 $ 0.22 Exercisable at end of the period 85,357,246 $ 0.19 68,742,315 $ 0.22 Weighted average remaining life 2.7 years 2.5 years
Schedule of Financial Statements with Respect to the EIPs	Amounts recognized in the financial statements with respect to the EIPs in the three months ended March 31, 2024 and 2023 were as follows: Three Months Ended 2024 2023 Total cost of share-based payment plans during the period $ 35,986 $ 82,951 Amounts capitalized in deferred equity compensation during period $ --- $ --- Amounts written off from deferred equity compensation during period $ 57,147 $ --- Amounts charged against income for amounts previously capitalized $ --- $ 5,150 Amounts charged against income, before income tax benefit $ 93,133 $ 88,101 Amount of related income tax benefit recognized in income $ --- $ ---
Schedule of Aggregate Grant Date Fair Value	The fair value of the warrants was calculated using the following range of assumptions: 2024 2023 Pricing model utilized Binomial Lattice Binomial Lattice Risk free rate range 3.97% to 4.20% 3.45% to 5.43% Expected life range (in years) 5.00 years to 10.00 years 0.28 years to 5.00 years Volatility range 140.94% to 173.25% 126.30% to 165.20% Dividend yield 0.00% 0.00% Expected forfeiture 33.00% 20.00%
Schedule of Fair Value of Options Granted	The fair value of options granted for the three months ended March 31, 2024 and 2023 was calculated using the following range of assumptions: 2024 2023 Pricing model utilized Binomial Lattice Binomial Lattice Risk free rate range 4.20% 3.48% Expected life range (in years) 10.00 years 10.00 years Volatility range 173.25% 145.03% Dividend yield 0.00% 0.00% Expected forfeiture 30.00% 30.00%
Warrant [Member]
Shareholders' Equity (Tables) [Line Items]
Schedule of Financial Statements with Respect to the EIPs	The following table summarizes information about the Company’s stock warrants outstanding as of March 31, 2024: Warrants Outstanding Warrants Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.0001 to 0.09 29,968,289 3.6 $ 0.07 29,968,289 $ 0.07 $ 0.10 to 0.24 25,436,940 3.0 $ 0.16 25,436,940 $ 0.16 $ 0.25 to 0.49 26,992,093 1.5 $ 0.31 26,992,093 $ 0.31 $ 0.50 to 1.05 2,959,924 2.3 $ 0.68 2,959,924 $ 0.68 $ 0.05 to 1.00 85,357,246 2.7 $ 0.19 85,357,246 $ 0.19
Stock Options [Member]
Shareholders' Equity (Tables) [Line Items]
Schedule of Stock Warrants	The following table summarizes stock option activity as of and for the three months ended March 31, 2024 and 2023: 2024 2023 Weighted Weighted Average Average Exercise Exercise Stock options Number Price Number Price Outstanding at beginning of period 5,093,738 $ 0.16 5,222,982 $ 0.20 Granted during the period 4,504,974 $ 0.06 93,750 $ 0.08 Exercised during the period --- $ --- --- $ --- Forfeited during the period (449,982 ) $ (0.21 ) (150,000 ) $ (0.16 ) Outstanding at end of period 9,148,730 $ 0.10 5,166,732 $ 0.17 Options exercisable at period-end 7,063,146 $ 0.11 3,108,565 $ (0.20 )
Schedule of Stock Grant Activity	The following table summarizes the status and activity of nonvested options issued pursuant to the EIPs as of and for the three months ended March 31, 2024 and 2023: 2024 2023 Weighted Weighted Average Average Grant Date Grant Date Stock options Shares Fair Value Shares Fair Value Nonvested options at beginning of period 1,073,084 $ 0.06 2,260,417 $ 0.08 Granted 4,504,974 $ 0.04 93,750 $ 0.05 Vested (3,442,474 ) $ (0.04 ) (196,000 ) $ (0.14 ) Forfeited (50,000 ) $ (0.08 ) (100,000 ) $ (0.09 ) Nonvested options at end of period 2,085,584 $ 0.05 2,058,167 $ 0.07
Stock Grants [Member]
Shareholders' Equity (Tables) [Line Items]
Schedule of Stock Grant Activity	The following table summarizes stock grant activity as of and for the three months ended March 31, 2024 and 2023: 2024 2023 Weighted Weighted Average Average Grant Date Grant Date Stock Grants Shares Fair Value Shares Fair Value Nonvested grants at beginning of period 1,484,488 $ 0.05 1,651,435 $ 0.05 Granted --- $ --- 160,944 $ 0.09 Vested (408,164 ) $ (0.05 ) (468,292 ) $ (0.05 ) Forfeited (50,000 ) $ (0.12 ) --- $ --- Nonvested grants at end of period 1,026,324 $ 0.05 1,344,087 $ 0.06

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2024
Operating lease [Member]
Commitments and Contingencies (Tables) [Line Items]
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities were as follows as of March 31, 2024: 2024 $ 390,027 2025 467,994 2026 335,634 2027 990 Total lease payments 1,194,645 Less interest (337,407 ) Present value of lease liabilities $ 857,238

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
Schedule of Segment Information	Segment information for the year ended three months ended March 31, 2024 was as follows: Three Months ended March 31, 2024 Health Services Digital Healthcare Medical Distribution Total Revenue Patient service revenue, net $ 963,621 $ --- $ --- $ 963,621 Subscription revenue --- 7,628 --- 7,628 Product and other revenue --- --- 32,983 32,983 Total revenue 963,621 7,628 32,983 1,004,232 Operating Expenses Practice salaries and benefits 583,156 --- --- 583,156 Other practice operating expenses 482,583 --- --- 482,583 Cost of product revenue --- --- 30,579 30,579 Selling, general and administrative expenses --- 980,174 19,269 999,443 Depreciation and amortization 85,169 1,340 --- 86,509 Total Operating Expenses 1,150,908 981,514 49,848 2,182,270 Income (loss) from operations $ (187,287 ) $ (973,886 ) $ (16,865 ) $ (1,178,038 ) Other Segment Information Loss on extinguishment of debt $ --- $ 96,660 $ --- $ 96,660 Amortization of original issue discounts on notes payable $ 108,265 $ --- $ --- $ 108,265 Change in fair value of contingent acquisition consideration $ --- $ (76 ) $ --- $ (76 ) Interest expense $ 3,881 $ 950 $ --- $ 4,831 Identifiable Assets Identifiable assets as of March 31, 2024 $ 1,635,387 $ 2,246,600 $ 8,772 $ 3,890,759 Identifiable assets as of December 31, 2023 $ 1,812,609 $ 2,457,849 $ 9,682 $ 4,280,140 Three Months Ended March 31, 2023 Health Services Digital Healthcare Medical Distribution Total Revenue Patient service revenue, net $ 1,700,281 $ --- $ --- $ 1,700,281 Subscription revenue --- 16,299 --- 16,299 Product and other revenue --- --- 38,574 38,574 Total revenue 1,700,281 16,299 38,574 1,755,154 Operating Expenses Practice salaries and benefits 963,657 --- --- 963,657 Other practice operating expenses 624,247 --- --- 624,247 Cost of product revenue --- --- 32,060 32,060 Selling, general and administrative expenses --- 1,070,321 33,427 1,103,748 Depreciation and amortization 86,672 1,405 --- 88,077 Total Operating Expenses 1,674,576 1,071,726 65,487 2,811,789 Income (loss) from operations $ 25,705 $ (1,055,427 ) $ (26,913 ) $ (1,056,635 ) Other Segment Information Interest expense (income) $ --- $ 44,763 $ --- $ 44,763 Financing cost $ 2,812 $ 8,569 $ --- $ 11,381 Amortization of original issue discounts on notes payable $ 60,993 $ 2,367 $ --- $ 63,360 Change in fair value of contingent acquisition consideration $ --- $ 1,706 $ --- $ 1,706 Identifiable Assets Identifiable assets as of March 31, 2023 $ 2,204,934 $ 3,606,105 $ 14,203 $ 5,825,242 Goodwill as of March 31, 2023 $ 319,958 $ --- $ --- $ 319,958

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value of Financial Instruments [Abstract]
Schedule of Fair Value Measurements	The following table summarizes the conclusions reached regarding fair value measurements as of March 31, 2024 and December 31, 2023: As of March 31, 2024 As of December 31, 2023 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Contingent sale consideration receivable $ --- $ --- $ 1,663,163 $ 1,663,163 $ --- $ --- $ 1,663,163 $ 1,663,163 Liabilities: Contingent acquisition consideration payable --- --- 2,113 2,113 --- --- 2,189 2,189 Convertible note payable to related party --- --- 199,621 199,621 --- --- --- --- $ --- $ --- $ 201,734 $ 201,734 $ --- $ --- $ 2,189 $ 2,189

Business and Business Present_2

Business and Business Presentation (Details) - shares	Mar. 31, 2024	Dec. 31, 2023	Feb. 05, 2018	Sep. 02, 2014
Business and Business Presentation (Details) [Line Items]
Number of authorized shares				250,000,000
Common stock shares authorized	500,000,000	500,000,000
Common Stock [Member]
Business and Business Presentation (Details) [Line Items]
Number of authorized shares				230,000,000
Common stock shares authorized			500,000,000
Preferred Stock [Member]
Business and Business Presentation (Details) [Line Items]
Number of authorized shares				20,000,000

Significant Accounting Polici_2

Significant Accounting Policies (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Significant Accounting Policies (Details) [Line Items]
FDIC insurance amount (in Dollars)	$ 250,000
Cash balances in excess of FDICI insured limit (in Dollars)	$ 0	$ 0
Percentage of customers accounts receivable billings	61%
Gross patient services accounts receivable (in Dollars)	$ 40,295	34,481
Net patient services accounts receivable (in Dollars)	33,620	20,861
Allowance of doubtful accounts (in Dollars)	$ 0	$ 0
Percentage of revenue	10%
Warrants outstanding	85,357,246	77,414,648
Stock options outstanding	7,063,146	5,093,738
Common shares issuable	1,055,536	2,764,352
Shares of common stock issuable	13,750,000	13,750,000
Employee Incentive Plan [Member]
Significant Accounting Policies (Details) [Line Items]
Unissued shares subject to future vesting	1,026,324	1,484,488
Minimum [Member]
Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	5 years
Maximum [Member]
Significant Accounting Policies (Details) [Line Items]
Estimated useful lives	7 years

Liquidity and Going Concern A_2

Liquidity and Going Concern Analysis (Details) - USD ($)								3 Months Ended
	Oct. 31, 2023	Aug. 31, 2023	Jul. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Jan. 17, 2023	Jul. 05, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Liquidity and Going Concern Analysis (Details) [Line Items]
Cash balance								$ 23,491
Working capital deficit								798,224
Capital deficit								(43,420,854)		$ (42,033,136)
Net income (loss)								(1,387,718)	$ 1,451,935
Operating activities								(854,855)	$ (1,099,513)
Agreement amount								500,000
Net incremental consideration			$ 1,225,000					500,000
Notes payable to related parties								221,278
Proceeds from the sale of common stock								$ 355,000
Shares of common stock (in Shares)							30,000,000
Common stock, par value (in Dollars per share)								$ 0.0001		$ 0.0001
SEPA [Member]
Liquidity and Going Concern Analysis (Details) [Line Items]
Shares of common stock (in Shares)									225,000
AHP Merger Agreement [Member]
Liquidity and Going Concern Analysis (Details) [Line Items]
Capital deficit								$ 43,420,854
Agreement amount					$ 31,381	$ 750,000
Net incremental consideration		$ 1,750,000	1,750,000	$ 1,750,000
Net after commissions	$ 1,873,993	$ 1,540,000	$ 1,540,000	$ 1,540,000				$ 1,873,993
Transfer milestones rate								100%
Commissions and other expenses	$ 1,186,231							$ 1,186,231
Common Stock [Member]
Liquidity and Going Concern Analysis (Details) [Line Items]
Common stock, par value (in Dollars per share)							$ 0.0001
Common Stock [Member] | SEPA [Member]
Liquidity and Going Concern Analysis (Details) [Line Items]
Proceeds amount									$ 18,765

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($)						3 Months Ended
	Oct. 31, 2023	Aug. 31, 2023	Jul. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Discontinued Operations [Line Items]
Definitive agreement					$ 750,000		$ 750,000
Stub Period Reimbursement					$ 31,381
Net incremental cash						$ 1,750,000
Net incremental cash consideration			$ 1,225,000			500,000
Gross receipts	$ 1,873,993					1,873,993
Net proceeds	1,186,231					$ 1,186,231
Aggregate merger consideration						1%
Cash consideration						$ 3,000,000
Net cash operations of division						0	(47,163)
Gain from disposal of discontinued operations						2,674,069
Other receivables						750,000
Stub period reimbursement						31,381	$ 31,381
PBACO [Member]
Discontinued Operations [Line Items]
Net incremental cash consideration			150,000
Net after commissions			120,000	$ 1,180,000
AHP Merger Agreement [Member]
Discontinued Operations [Line Items]
Net incremental cash consideration		$ 1,750,000	1,750,000	1,750,000
Net after commissions	1,873,993	$ 1,540,000	$ 1,540,000	$ 1,540,000		$ 1,873,993
Transfer milestones rate						100%
Other expenses	$ 1,186,231					$ 1,186,231

Discontinued Operations (Deta_2

Discontinued Operations (Details) - Schedule of Financial Results of the ACO/MSO Division - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue		$ 23,646
Operating Expenses and Costs:
Medicare shared savings expenses		67,935
Loss from operations of discontinued operations before income taxes		(44,289)
Provision for income taxes
Loss from discontinued operations, net of income taxes		(44,289)
Consulting revenue [Member]
Revenue:
Total revenue		$ 23,646

Discontinued Operations (Deta_3

Discontinued Operations (Details) - Schedule of Fair Value of Consideration Received and Receivable - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Fair Value of Consideration Received and Receivable [Line Items]
Upfront Cash Consideration paid at signing	$ 750,000
Incremental Cash Consideration	1,311,567
IPO Share Consideration	1,463,517
2022 MSSP Consideration	312,987
Physician Advance Consideration	199,645
Stub Period Reimbursement	31,381	$ 31,381
Total fair value of contingent consideration receivable	3,319,097
Total fair value of consideration received and receivable	$ 4,069,097	$ 4,069,097

Discontinued Operations (Deta_4

Discontinued Operations (Details) - Schedule of Assets and Liabilities Derecognized	Mar. 31, 2024 USD ($)
Schedule of Assets and Liabilities Derecognized [Line Items]
Prepaid expenses	$ 1,500
Intangible asset - ACO physician contract	1,073,000
Goodwill	381,856
Contract liability	(20,278)
Contingent acquisition consideration	(185,024)
Net Book Value of Assets and Liabilities Sold	$ 1,251,054

Discontinued Operations (Deta_5

Discontinued Operations (Details) - Schedule of Fair Value of Consideration and Derecognition of Assets and Liabilities - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Schedule of Fair Value of Consideration and Derecognition of Assets and Liabilities [Line Items]
Total fair value of consideration received and receivable	$ 4,069,097	$ 4,069,097
Less: net book value of assets and liabilities sold		(1,251,054)
Less: fair value of Indemnification Clause	(143,974)	(143,974)	$ (143,974)
Gain from disposal of discontinued operations		$ 2,674,069

Discontinued Operations (Deta_6

Discontinued Operations (Details) - Schedule of Remaining Unresolved of Contingent Consideration Receivable	3 Months Ended
	Mar. 31, 2024 USD ($)
Schedule of Remaining Unresolved of Contingent Consideration Receivable [Line Items]
IPO Share Consideration	$ 1,463,518
Physician Advance Consideration	199,645
Remaining contingent sale consideration receivable	$ 1,663,163

Prepaid Expenses and Other (Det

Prepaid Expenses and Other (Details) - Schedule of Prepaid and Other Expenses - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Prepaid Expenses and Other [Abstract]
Insurance prepayments	$ 7,791	$ 11,209
Other expense prepayments	22,475	38,391
Rent deposits	50,047	50,547
Contract assets	9,750	5,110
Total prepaid expenses and other	90,063	105,257
Less: long term portion	(50,047)	(50,047)
Prepaid expenses and other, current portion	$ 40,016	$ 55,210

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 29,469	$ 31,037

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property, Plant and Equipment - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Property, Plant and Equipment [Line Items]
Total property, plant and equipment, Gross	$ 814,415	$ 811,817
Less: accumulated depreciation	(550,531)	(521,062)
Property, plant and equipment, net	263,884	290,755
Medical Equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total property, plant and equipment, Gross	496,452	493,854
Furniture, Office Equipment and Leasehold Improvements [Member]
Schedule of Property, Plant and Equipment [Line Items]
Total property, plant and equipment, Gross	$ 317,963	$ 317,963

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Intangible Assets and Goodwill [Line Items]
Amortization expense	$ 57,040	$ 57,040

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	$ 1,142,538	$ 1,142,538
Less: accumulated amortization	(315,730)	(258,690)
Intangible assets, net	826,808	883,848
NCFM: Medical database [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	1,101,538	1,101,538
NCFM: Website [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	$ 41,000	$ 41,000

Intangible Assets (Details) -_2

Intangible Assets (Details) - Schedule of Future Amortization Expense of Intangible Assets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule Of Future Amortization Expense Of Intangible Assets Abstract
2024 (April to December)	$ 165,885
2025	220,308
2026	220,308
2027	220,307
Thereafter
Total future amortization expense	$ 826,808	$ 883,848

Leases (Details)

Leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Leases [Line Items]
Weighted-average remaining lease term to operating leases	2 years 4 months 24 days
Weighted-average discount rate	15.44%
Lease expense	$ 129,431	$ 111,905

Leases (Details) - Schedule of

Leases (Details) - Schedule of Lease-Related Assets and Liabilities - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Lease-Related Assets and Liabilities [Line Items]
Lease assets	$ 853,525	$ 935,812
Lease liabilities
Lease liabilities (short term)	332,692	326,033
Lease liabilities (long term)	524,546	613,386
Total lease liabilities	$ 857,238	$ 939,419

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Maturities of Operating Lease Liabilities - Operating Leases [Member]	Mar. 31, 2024 USD ($)
Leases (Details) - Schedule of Maturities of Operating Lease Liabilities [Line Items]
2024	$ 390,027
2025	467,994
2026	335,634
2027	990
Total lease payments	1,194,645
Less interest	(337,407)
Present value of lease liabilities	$ 857,238

Accounts Payable, Accrued Exp_3

Accounts Payable, Accrued Expenses and Other Current Liabilities (Details) - USD ($)			3 Months Ended
	Dec. 31, 2024	Oct. 31, 2023	Mar. 31, 2024	Dec. 31, 2023
Accounts Payable, Accrued Expenses and Other Current Liabilities (Details) [Line Items]
Gross receipts		$ 1,873,993	$ 1,873,993
Net proceeds		$ 1,186,231	1,186,231
Accrued commissions and other fees payable				$ 100,000
Cash consideration paid			$ 75,000
Forecast [Member]
Accounts Payable, Accrued Expenses and Other Current Liabilities (Details) [Line Items]
Acquisition consideration	$ 2,113

Accounts Payable, Accrued Exp_4

Accounts Payable, Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities - USD ($)		Mar. 31, 2024	Dec. 31, 2023
Schedule Of Accounts Payable And Accrued Expenses [Abstract]
Trade accounts payable		$ 372,612	$ 251,479
Accrued payroll liabilities		76,646	110,103
Accrued operating expenses		175,349	91,238
Accrued interest		52,287	57,074
Accrued commissions payable from 2022 MSSP Consideration	[1]	25,000	100,000
Contingent acquisition consideration payable	[2]	2,113	2,189
Product return allowance		1,117	2,095
Total		$ 705,124	$ 614,178
[1]During September 2023, AHP received from the CMS a final determination of AHP’s Plan Year 2022 MSSP shared savings, of which the Company realized gross receipts of $1,873,993 and net proceeds of $1,186,231 after payments to participating physicians and commissions in satisfaction of the 2022 MSSP Consideration. Gross payment was received by the Company in October 2023. As of December 31, 2023, the Company’s remaining accrued commissions and other fees payable resulting from the receipt and prior consideration received in the amount of $100,000, of which $75,000 was paid in the three months ended March 31, 2024. See Note 4 for complete description of the AHP Sale and related consideration.[2]Contingent acquisition consideration reflects the fair value of the final earn-out payment potentially payable related to the Company’s acquisitions of MOD in 2020.  All of the remaining $2,113 contingent acquisition consideration related to MOD matures in 2024 based on the performance of the business unit for the year ended December 31, 2024.

Contract Liabilities (Details)

Contract Liabilities (Details) - Schedule of Amounts Related to Contract Liabilities - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Contract Liabilities (Details) - Schedule of Amounts Related to Contract Liabilities [Line Items]
Contract liabilities	$ 331,440	$ 271,774
Patient services paid but not provided - NCFM [Member]
Contract Liabilities (Details) - Schedule of Amounts Related to Contract Liabilities [Line Items]
Contract liabilities	175,333	95,334
Patient services paid but not provided - BTG [Member]
Contract Liabilities (Details) - Schedule of Amounts Related to Contract Liabilities [Line Items]
Contract liabilities	90,599	100,857
Patient services paid but not provided – NWC [Member]
Contract Liabilities (Details) - Schedule of Amounts Related to Contract Liabilities [Line Items]
Contract liabilities	64,114	75,438
Unshipped products – MOD [Member]
Contract Liabilities (Details) - Schedule of Amounts Related to Contract Liabilities [Line Items]
Contract liabilities	$ 1,394	$ 145

Amounts Due to Related Party _3

Amounts Due to Related Party and Related Party Transactions (Details) - USD ($)									3 Months Ended		12 Months Ended
	Mar. 27, 2024	Dec. 01, 2023	Mar. 14, 2023	Feb. 14, 2023	Jan. 13, 2023	Jan. 05, 2023	Dec. 13, 2022	Nov. 08, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Jun. 26, 2023	Apr. 30, 2023
Related Party Transaction [Line Items]
Note payable amount									$ 221,278
Amortization of debt discount									$ 10,971	$ 0
Warrants issued (in Shares)									9,160,000	3,141,554
Interest expense									$ 6,046		$ 4,219
Loss on extinguishment of debt									(96,660)	$ (44,763)
Net proceeds										100,000
Repayments									183,676	200,593
Common stock at a fixed conversion price (in Dollars per share)	$ 0.0573
Warrants to purchase shares (in Shares)	6,660,000
Carrying value											0
Fair value of note													$ 13,077
Deferred compensation payable									300,600		300,600
Compensation received									0
March 2024 Warrant [Member]
Related Party Transaction [Line Items]
Fair value of the warrants	$ 254,345
Note Payable [Member]
Related Party Transaction [Line Items]
Discount against note payable									104,288		166,487
Unsecured Promissory Note [Member]
Related Party Transaction [Line Items]
Loss on extinguishment of debt										3,582
Unsecured Promissory Note [Member] | March 2024 Warrant [Member]
Related Party Transaction [Line Items]
Exercise price (in Dollars per share)	$ 0.06
Dr. Dent [Member]
Related Party Transaction [Line Items]
Interest rate						15%
Notes and Convertible Notes Payable [Member]
Related Party Transaction [Line Items]
Interest accrued									3,202		7,456
Loan [Member]
Related Party Transaction [Line Items]
Interest expense									3,202	3,890
Other Related Transactions [Member]
Related Party Transaction [Line Items]
Compensation received									20,000
Dr Dent [Member]
Related Party Transaction [Line Items]
Consulting fees									39,038	27,885
Dr Dent [Member] | Unsecured Promissory Note [Member]
Related Party Transaction [Line Items]
Note payable amount						$ 10,000
Discount against note payable						$ 3,851
Amortization of debt discount										269
Exercise price (in Dollars per share)						$ 0.104
Fair value of the warrants						$ 6,843
Face value						$ 10,000
Warrants issued (in Shares)						96,154
Interest expense										53
January 2023 Dent Note [Member]
Related Party Transaction [Line Items]
Amortization of debt discount					$ 1,373
Interest expense					397
Loss on extinguishment of debt										41,181
January 2023 Dent Note [Member] | Note Payable [Member]
Related Party Transaction [Line Items]
Note payable amount					161,000
Discount against note payable					$ 42,553
January 2023 Dent Note [Member] | Unsecured Promissory Note [Member]
Related Party Transaction [Line Items]
Exercise price (in Dollars per share)					$ 0.093
Fair value of the warrants					$ 56,123
Face value					$ 161,000
Interest rate					15%
Warrants issued (in Shares)					860,215
Net proceeds					$ 160,000
Original issue discount					$ 1,000
February 2023 Dent Note [Member] | Note Payable [Member]
Related Party Transaction [Line Items]
Note payable amount				$ 186,000
February 2023 Dent Note [Member] | Unsecured Promissory Note [Member]
Related Party Transaction [Line Items]
Discount against note payable				$ 50,989
Amortization of debt discount										1,373
Exercise price (in Dollars per share)				$ 0.135
Fair value of the warrants				$ 66,136
Face value				$ 186,000
Interest rate				15%
Warrants issued (in Shares)				685,185
Interest expense										3,440
Net proceeds				$ 185,000
Original issue discount				$ 1,000
March 2023 Dent Note [Member]
Related Party Transaction [Line Items]
Discount against note payable			$ 26,011
Payment amount									12,601
Amortization of debt discount									2,504	1,292
March 2023 Dent Note [Member] | Promissory Note [Member]
Related Party Transaction [Line Items]
Note payable amount			126,011
Discount against note payable			26,011
Payment amount									12,601	0
Net proceeds			100,000
Original issue discount			12,510
Principal amount			112,510
Prepaid interest			13,501
Repayments			$ 126,011
Maturity date			Mar. 14, 2024
Discount rate			15%
June 2023 Dent Note [Member] | Unsecured Promissory Note [Member]
Related Party Transaction [Line Items]
Note payable amount												$ 26,875
Discount against note payable												1,875
Payment amount									25,000		0
Amortization of debt discount									0	1,292
Face value												25,000
Fixed interest												$ 1,875
Fixed interest rate												15%
December 2023 Dent Note [Member]
Related Party Transaction [Line Items]
Amortization of debt discount									32,330	0
December 2023 Dent Note [Member] | Unsecured Promissory Note [Member]
Related Party Transaction [Line Items]
Note payable amount		$ 166,500
Discount against note payable		$ 48,769
Payment amount									0	0
Exercise price (in Dollars per share)		$ 0.06
Face value		$ 150,000
Warrants issued (in Shares)		1,500,000
Net proceeds		$ 150,000
Maturity date		Feb. 28, 2024
Fixed interest		$ 15,000
Fixed interest rate		10%
Fixed fees		$ 1,500
Fair value warrants		$ 32,269
March 2024 Dent Note I [Member]
Related Party Transaction [Line Items]
Discount against note payable									203,588
Amortization of debt discount									8,852
Principal amount	$ 150,000
Net proceeds									350,000
Remaining principal payments									350,000		0
Carrying value									155,264		0
Interest accrued									460		0
March 2024 Dent Note I [Member] | Note Payable [Member]
Related Party Transaction [Line Items]
Interest rate	12%
Principal amount	$ 350,000
March 2024 Dent Note II [Member]
Related Party Transaction [Line Items]
Discount against note payable									89,222
Amortization of debt discount									2,379
Net proceeds									150,000
Remaining principal payments									150,000		0
Carrying value									63,157		0
Interest accrued									197		0
March 2024 Dent Note II [Member] | Note Payable [Member]
Related Party Transaction [Line Items]
Interest rate	12%
Maturity date	Aug. 24, 2024
March 2024 Dent Note III [Member]
Related Party Transaction [Line Items]
Fair value of the warrants									33,121
Loss on extinguishment of debt									96,660
Principal amount									166,500
Remaining principal payments									166,500		0
Carrying value									199,621
Interest accrued									219		$ 0
Fair value of note									199,621
March 2024 Dent Note III [Member] | March 2024 Warrant [Member]
Related Party Transaction [Line Items]
Fair value of the warrants									63,539
March 2024 Dent Note III [Member] | Note Payable [Member]
Related Party Transaction [Line Items]
Interest rate	12%
Principal amount	$ 166,500
Maturity date	Aug. 28, 2024
November Merchant cash Advance Factoring Agreement [Member]
Related Party Transaction [Line Items]
Advance received								$ 150,000
Loan repayment								3,750
Repaid amount								195,000
Note payable amount								195,000
Amortization of debt discount									0	11,219
November Merchant cash Advance Factoring Agreement [Member] | Note Payable [Member]
Related Party Transaction [Line Items]
Discount against note payable								$ 45,000
Payment amount									0	33,750
Merchant Cash Advance Factoring Agreement [Member]
Related Party Transaction [Line Items]
Advance received							$ 110,000
December Merchant Cash Advance Factoring Agreement [Member]
Related Party Transaction [Line Items]
Loan repayment							2,750
Repaid amount							143,000
Note payable amount							$ 143,000
Amortization of debt discount									0	17,070
Warrants issued (in Shares)							3,142,857
Exercise price (in Dollars per share)							$ 0.035
Fair value of the warrants							$ 63,420
December Merchant Cash Advance Factoring Agreement [Member] | Note Payable [Member]
Related Party Transaction [Line Items]
Discount against note payable							$ 68,281
Payment amount									$ 0	$ 24,750
Director [Member]
Related Party Transaction [Line Items]
Shares issuable (in Shares)									816,328		408,164

Amounts Due to Related Party _4

Amounts Due to Related Party and Related Party Transactions (Details) - Schedule of Amounts Due to Related Parties - Dr. Michael Dent [Member] - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Amounts Due to Related Parties [Line Items]
Face value of notes payable to related party	$ 699,621	$ 205,976
Less: unamortized discounts	(281,579)	(34,834)
Notes payable to related party, total	418,042	171,142
Plus deferred compensation payable to Dr. Michael Dent	300,600	300,600
Total due to related party	718,642	471,742
Note Payable, March 2023 [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Note Payable		12,601
Note Payable, June 2023 [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Note Payable		26,875
Note Payable, December 2023 [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Note Payable		166,500
Convertible Note Payable I [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Convertible Note Payable	150,000
Convertible Note Payable II [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Convertible Note Payable	350,000
Convertible Note Payable III [Member]
Schedule of Amounts Due to Related Parties [Line Items]
Convertible Note Payable	$ 199,621

Notes Payable (Details)

Notes Payable (Details) - USD ($)											3 Months Ended		12 Months Ended
	Mar. 27, 2024	Dec. 13, 2023	Dec. 12, 2023	Nov. 03, 2023	Aug. 08, 2023	Mar. 31, 2023	Mar. 10, 2023	Nov. 04, 2022	Oct. 21, 2022	Jul. 19, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Aug. 31, 2023	Apr. 30, 2023	Nov. 30, 2022	May 13, 2022	Aug. 31, 2020	Jul. 31, 2020	Jun. 30, 2020
Notes Payable (Details) [Line Items]
Disaster relief loans											$ 450,000		$ 450,000
Accrued on government and vendor notes payable											52,287		57,074
Interest expense on the loans											6,046		4,219
Interest income											6,579
Principal payments													450,000	$ 450,000
Net Carrying amount													450,000	450,000
Accrued interest										5%
Payment premium percentage										2%
Amortization expense note discount											10,971	$ 0
Payments to outstanding balance												0
Monthly payments																$ 13,077
Conversion price per share (in Dollars per share)	$ 0.0573
Remaining principal amount													189,000
SBA Loans [Member]
Notes Payable (Details) [Line Items]
Accrued on government and vendor notes payable											27,095		27,628
Loan [Member]
Notes Payable (Details) [Line Items]
Interest expense on the loans											3,202	3,890
Interest income													5,117
AEU Notes Payable [Member]
Notes Payable (Details) [Line Items]
Principal amount																		$ 550,000
Net proceeds								$ 35,800
Amortization expense note discount											0	2,367
Payments to outstanding balance											0	18,632
Gross amount								41,009
Recognized discount amount								$ 5,209
July 19, 2022 Notes Payable [Member]
Notes Payable (Details) [Line Items]
Interest rate, percentage										0%
Maturity date										Jan. 19, 2023
Net proceeds										$ 522,500
Total cash repayments										561,000
Discount against note										$ 38,500
Proceeds of sales						$ 18,765
October 2022 Note Payable [Member]
Notes Payable (Details) [Line Items]
Principal amount									$ 144,760
Net proceeds									125,000
Discount against note									37,131
Amortization expense note discount														10,745
Payments to outstanding balance														32,426
Original issue discount									15,510
Other fees									$ 4,250
Monthly payments																	$ 16,213
March 2023 Note Payable [Member]
Notes Payable (Details) [Line Items]
Principal amount							$ 116,760
Maturity date							Mar. 10, 2024
Net proceeds							$ 100,000
Discount against note											30,771
Original issue discount							12,510
Other fees							4,250
Prepaid interest							14,011
Total repayments							$ 130,771
March 2023 Note [Member]
Notes Payable (Details) [Line Items]
Amortization expense note discount											0	1,529
Note payable August 2023 [Member]
Notes Payable (Details) [Line Items]
Net Carrying amount													76,549	54,488
Principal amount					$ 144,760
Net proceeds					125,000
Original issue discount					15,510
Other fees					4,250
Monthly payments													16,213
Prepaid interest					17,371
Total repayments					$ 162,131
Remaining principal payments													97,279	$ 64,853
Conversion right discount, percentage															15%
May 2023 Notes Payable [Member]
Notes Payable (Details) [Line Items]
Net proceeds											37,131
Discount against note													37,131
August 2023 Note [Member]
Notes Payable (Details) [Line Items]
Amortization expense note discount											10,365	0
Payments to outstanding balance											32,426	0
November 2023 Note [Member]
Notes Payable (Details) [Line Items]
Net Carrying amount											195,600		253,000
Principal amount				$ 350,000
Net proceeds				317,000
Total cash repayments				378,000
Discount against note				$ 61,000
Amortization expense note discount													18,200
Payments to outstanding balance											75,600	0
Remaining principal payments											226,800		302,400
Interest rate, percentage				0%
Original issue discount, percentage				8%
Repaid cash premium, percentage				8%
December 2023 Note I Notes Payable [Member]
Notes Payable (Details) [Line Items]
Net Carrying amount											89,612		127,291
Principal amount			$ 144,760
Net proceeds			125,000
Original issue discount			15,510
Other fees			4,250
Monthly payments			16,213
Prepaid interest			17,371
Total repayments			$ 162,131
Remaining principal payments											$ 113,482		162,131
Conversion right discount, percentage											15%
Note Payable December 2023 Note [Member]
Notes Payable (Details) [Line Items]
Payments to outstanding balance											$ 48,649	0
Notes Payable September 2023 [Member]
Notes Payable (Details) [Line Items]
Principal amount		$ 175,000
December 2023 Note II Notes Payable [Member]
Notes Payable (Details) [Line Items]
Net Carrying amount											123,147		$ 127,483
Net proceeds		156,000
Total cash repayments		189,000
Discount against note		$ 66,000
Amortization expense note discount											22,664	$ 0
Payments to outstanding balance											27,000
Interest rate, percentage		0%
Original issue discount, percentage		8%
Repaid cash premium, percentage		8%
Conversion price per share (in Dollars per share)		$ 0.05
Yorkville [Member] | December 2023 Note II Notes Payable [Member]
Notes Payable (Details) [Line Items]
Remaining principal amount											162,000
Subsidiaries [Member]
Notes Payable (Details) [Line Items]
Disaster relief loans																			$ 450,000	$ 450,000	$ 450,000
Percentage of loans bear interest																			3.75%	3.75%	3.75%
Maturity term																			30 years	30 years	30 years
Notes Payable, Other Payables [Member]
Notes Payable (Details) [Line Items]
Amortization expense note discount						4,748					0
Payments to outstanding balance											$ 0
Notes Payable, Other Payables [Member] | July 19, 2022 Notes Payable [Member]
Notes Payable (Details) [Line Items]
Payments to outstanding balance						$ 168,300

Notes Payable (Details) - Sched

Notes Payable (Details) - Schedule of Notes Payable - Note Payable [Member] - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Notes Payable [Line Items]
Face value of notes payable	$ 1,017,135	$ 1,200,810
Less: unamortized discounts	(104,288)	(166,487)
Notes payable, total	912,847	1,034,323
Less: long term portion	(450,000)	(450,000)
Notes payable, current portion	462,847	584,323
SBA Disaster Relief Loans [Member]
Schedule of Notes Payable [Line Items]
Face value of notes payable	450,000	450,000
1800 Diagonal Note Payable III, August 2023 [Member]
Schedule of Notes Payable [Line Items]
Face value of notes payable	64,853	97,279
Yorkville Note Payable III, November 2023 [Member]
Schedule of Notes Payable [Line Items]
Face value of notes payable	226,800	302,400
1800 Diagonal Note Payable III, December 2023 [Member]
Schedule of Notes Payable [Line Items]
Face value of notes payable	113,482	162,131
Yorkville Note Payable III, December 2023 [Member]
Schedule of Notes Payable [Line Items]
Face value of notes payable	$ 162,000	$ 189,000

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($)		3 Months Ended
	Jul. 05, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Jul. 11, 2022	Sep. 09, 2021	Jan. 01, 2016
Shareholder’s Equity [Line Items]
Shares of common stock (in Shares)		281,064,958		275,964,958
Common stock par value (in Dollars per share)		$ 0.0001		$ 0.0001
Aggregate daily volume percentage	30%
Purchase percentage	96%
Shares of common stock underlying (in Shares)					30,000,000
Proceeds for the issuance of common stock		$ 355,000	$ 200,000
Sale of shares (in Shares)	30,000,000
Issued warrants (in Shares)		9,160,000	3,141,554
Exercise price per share (in Dollars per share)		$ 0.0569	$ 0.09
Aggregate grant date fair value		$ 385,633	$ 246,063
Total unrecognized compensation cost		$ 10,449
Weighted-average period		1 year 6 months
Fair value options granted (in Dollars per share)		$ 0.04
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value			26,845
Aggregate grant fair value		$ 20,000	$ 22,460
Amortization of deferred stock compensation		$ 0
Stock Option [Member]
Shareholder’s Equity [Line Items]
Fair value options granted (in Dollars per share)		$ 0.04	$ 0.14
Stock based compensation expense		$ 47,900	$ 22,511
Minimum [Member]
Shareholder’s Equity [Line Items]
Exercise price per share (in Dollars per share)		$ 3
Maximum [Member]
Shareholder’s Equity [Line Items]
Amortization of deferred stock compensation			5,150
2021 EIP [Member]
Shareholder’s Equity [Line Items]
Issuance of common stock (in Shares)						20,000,000
Employee Equity Incentive Plan [Member]
Shareholder’s Equity [Line Items]
Total unrecognized compensation cost		$ 78,222
Weighted-average period		1 year 8 months 12 days
Stock based compensation expense		$ 35,986	82,951
Common Stock [Member]
Shareholder’s Equity [Line Items]
Shares of common stock (in Shares)	2,000,000
Common stock par value (in Dollars per share)	$ 0.0001
Proceeds for the issuance of common stock			$ 225,000
Common Stock [Member] | Warrant [Member]
Shareholder’s Equity [Line Items]
Exercise price per share (in Dollars per share)		$ 0.17
Stock Option [Member] | Minimum [Member]
Shareholder’s Equity [Line Items]
Fair value options granted (in Dollars per share)			$ 0.05
Employee Equity Incentive Plan [Member]
Shareholder’s Equity [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value		$ 137,040
Stock Based Compensation [Member]
Shareholder’s Equity [Line Items]
Stock based compensation expense		$ 1,796	$ 25,467
SEPA [Member]
Shareholder’s Equity [Line Items]
Shares of common stock (in Shares)	30,000,000
SEPA [Member] | Common Stock [Member]
Shareholder’s Equity [Line Items]
Shares of common stock (in Shares)	30,000,000
Common stock par value (in Dollars per share)	$ 0.0001
Proceeds for the issuance of common stock			18,765
Consultants [Member] | Common Stock [Member]
Shareholder’s Equity [Line Items]
Purchase of shares (in Shares)		2,504,974
Yorkville [Member]
Shareholder’s Equity [Line Items]
Owning percentage	4.99%
Common Stock [Member] | 2016 EIP [Member]
Shareholder’s Equity [Line Items]
Shares issued (in Shares)							15,503,680
Private Placement [Member]
Shareholder’s Equity [Line Items]
Proceeds for the issuance of common stock		$ 355,000	$ 200,000
Sale of shares (in Shares)		5,100,000
Private Placement [Member] | Warrant [Member]
Shareholder’s Equity [Line Items]
Issued warrants (in Shares)		2,500,000
Private Placement [Member] | Common Stock [Member]
Shareholder’s Equity [Line Items]
Sale of shares (in Shares)			2,000,000
Private Placement [Member] | Common Stock [Member] | Warrant [Member]
Shareholder’s Equity [Line Items]
Issued warrants (in Shares)			1,500,000
Exercise price per share (in Dollars per share)			$ 0.2

Shareholders' Equity (Details)

Shareholders' Equity (Details) - Schedule of Company Obligated to Issue Shares - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Company Obligated to Issue Shares [Line Items]
Shares issuable to employees and consultants	$ 54,570	$ 281,682
Shares issuable to independent directors	1,055,536	2,764,352
Shares Issuable to Employees and Consultants [Member]
Schedule of Company Obligated to Issue Shares [Line Items]
Shares issuable to employees and consultants	$ 14,570	$ 261,682
Shares issuable to independent directors	239,208	2,356,188
Shares Issuable to Independent Directors [Member]
Schedule of Company Obligated to Issue Shares [Line Items]
Shares issuable to employees and consultants	$ 40,000	$ 20,000
Shares issuable to independent directors	816,328	408,164

Shareholders' Equity (Details_2

Shareholders' Equity (Details) - Schedule of Stock Warrants - Warrant [Member] - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Stock Warrants [Line Items]
Number, Outstanding, beginning balance	77,414,648	68,109,094
Weighted Average Exercise Price, Outstanding, beginning balance	$ 0.2	$ 0.23
Number, Outstanding, ending balance	85,357,246	68,742,315
Weighted Average Exercise Price, Outstanding, ending balance	$ 0.19	$ 0.22
Number, Options exercisable at period-end	85,357,246	68,742,315
Weighted Average Exercise Price, Options exercisable at period-end	$ 0.19	$ 0.22
Weighted average remaining life	2 years 8 months 12 days	2 years 6 months
Number, Granted during the period	9,160,000	3,141,554
Weighted Average Exercise Price, Granted during the period	$ 0.09	$ 0.15
Number of Exercised during the period
Weighted Average Exercise Price, Exercised during the period
Number, Expired during the period	(1,217,402)	(2,508,333)
Weighted Average Exercise Price, Expired during the period	$ (0.28)	$ (0.25)

Shareholders' Equity (Details_3

Shareholders' Equity (Details) - Schedule of Financial Statements with Respect to the EIPs - Warrant [Member]	3 Months Ended
	Mar. 31, 2024 $ / shares shares
0.0001 to 0.09 [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding Number Outstanding (in Shares) | shares	29,968,289
Warrants Outstanding Weighted-Average Remaining Contractual Life (years)	3 years 7 months 6 days
Warrants Outstanding Weighted-Average Exercise Price	$ 0.07
Warrants Exercisable Number Exercisable (in Shares) | shares	29,968,289
Warrants Exercisable Weighted-Average Exercise Price	$ 0.07
0.0001 to 0.09 [Member] | Minimum [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding, Exercise Prices	0.0001
0.0001 to 0.09 [Member] | Maximum [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding, Exercise Prices	$ 0.09
0.10 to 0.24 [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding Number Outstanding (in Shares) | shares	25,436,940
Warrants Outstanding Weighted-Average Remaining Contractual Life (years)	3 years
Warrants Outstanding Weighted-Average Exercise Price	$ 0.16
Warrants Exercisable Number Exercisable (in Shares) | shares	25,436,940
Warrants Exercisable Weighted-Average Exercise Price	$ 0.16
0.10 to 0.24 [Member] | Minimum [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding, Exercise Prices	0.1
0.10 to 0.24 [Member] | Maximum [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding, Exercise Prices	$ 0.24
0.25 to 0.49 [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding Number Outstanding (in Shares) | shares	26,992,093
Warrants Outstanding Weighted-Average Remaining Contractual Life (years)	1 year 6 months
Warrants Outstanding Weighted-Average Exercise Price	$ 0.31
Warrants Exercisable Number Exercisable (in Shares) | shares	26,992,093
Warrants Exercisable Weighted-Average Exercise Price	$ 0.31
0.25 to 0.49 [Member] | Minimum [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding, Exercise Prices	0.25
0.25 to 0.49 [Member] | Maximum [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding, Exercise Prices	$ 0.49
0.50 to 1.05 [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding Number Outstanding (in Shares) | shares	2,959,924
Warrants Outstanding Weighted-Average Remaining Contractual Life (years)	2 years 3 months 18 days
Warrants Outstanding Weighted-Average Exercise Price	$ 0.68
Warrants Exercisable Number Exercisable (in Shares) | shares	2,959,924
Warrants Exercisable Weighted-Average Exercise Price	$ 0.68
0.50 to 1.05 [Member] | Minimum [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding, Exercise Prices	0.5
0.50 to 1.05 [Member] | Maximum [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding, Exercise Prices	$ 1.05
0.05 to 1.00 [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding Number Outstanding (in Shares) | shares	85,357,246
Warrants Outstanding Weighted-Average Remaining Contractual Life (years)	2 years 8 months 12 days
Warrants Outstanding Weighted-Average Exercise Price	$ 0.19
Warrants Exercisable Number Exercisable (in Shares) | shares	85,357,246
Warrants Exercisable Weighted-Average Exercise Price	$ 0.19
0.05 to 1.00 [Member] | Minimum [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding, Exercise Prices	0.05
0.05 to 1.00 [Member] | Maximum [Member]
Schedule of Stock Warrants Outstanding [Line Items]
Warrants Outstanding, Exercise Prices	$ 1

Shareholders' Equity (Details_4

Shareholders' Equity (Details) - Schedule of Aggregate Grant Date Fair Value	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Aggregate Grant Date Fair Value [Line Items]
Pricing model utilized	Binomial Lattice	Binomial Lattice
Dividend yield	0%	0%
Expected forfeiture	33%	20%
Minimum [Member]
Schedule of Aggregate Grant Date Fair Value [Line Items]
Risk free rate range	3.97%	3.45%
Expected life range (in years)	5 years	3 months 10 days
Volatility range	140.94%	126.30%
Maximum [Member]
Schedule of Aggregate Grant Date Fair Value [Line Items]
Risk free rate range	4.20%	5.43%
Expected life range (in years)	10 years	5 years
Volatility range	173.25%	165.20%

Shareholders' Equity (Details_5

Shareholders' Equity (Details) - Schedule of Financial Statements with Respect to the EIPs - Employee Equity Incentives Plans [Member - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Financial Statements with Respect to the EIPs [Line Items]
Total cost of share-based payment plans during the period	$ 35,986	$ 82,951
Amounts capitalized in deferred equity compensation during period
Amounts written off from deferred equity compensation during period	57,147
Amounts charged against income for amounts previously capitalized		5,150
Amounts charged against income, before income tax benefit	93,133	88,101
Amount of related income tax benefit recognized in income

Shareholders' Equity (Details_6

Shareholders' Equity (Details) - Schedule of Stock Warrants - Stock Option [Member] - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Stock Option Activity [Line Items]
Number, Beginning Balance	5,093,738	5,222,982
Weighted Average Exercise Price, Beginning Balance	$ 0.16	$ 0.2
Number, Granted during the period	4,504,974	93,750
Weighted Average Exercise Price, Granted during the period	$ 0.06	$ 0.08
Number, Exercised during the period
Weighted Average Exercise Price, Exercised during the period
Number, Forfeited during the period	(449,982)	(150,000)
Weighted Average Exercise Price, Forfeited during the period	$ (0.21)	$ (0.16)
Number, Ending Balance	9,148,730	5,166,732
Weighted Average Exercise Price, Ending Balance	$ 0.1	$ 0.17
Number, Options exercisable at period-end	7,063,146	3,108,565
Weighted Average Exercise Price, Options exercisable at period-end	$ 0.11	$ (0.2)

Shareholders' Equity (Details_7

Shareholders' Equity (Details) - Schedule of Fair Value of Options Granted - Stock Option [Member]	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Fair Value of Options Granted [Line Items]
Pricing model utilized	Binomial Lattice	Binomial Lattice
Risk free rate range	4.20%	3.48%
Expected life range (in years)	10 years	10 years
Volatility range	173.25%	145.03%
Dividend yield	0%	0%
Expected forfeiture	30%	30%

Shareholders' Equity (Details_8

Shareholders' Equity (Details) - Schedule of Stock Grant Activity - Stock Options [Member] - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Non-Vested Options Issued [Line Items]
Shares, Nonvested at beginning of period	1,073,084	2,260,417
Weighted Average Grant Date Fair Value, Nonvested at beginning of period	$ 0.06	$ 0.08
Shares, Granted	4,504,974	93,750
Weighted Average Grant Date Fair Value, Granted	$ 0.04	$ 0.05
Shares, Vested	(3,442,474)	(196,000)
Weighted Average Grant Date Fair Value, Vested	$ (0.04)	$ (0.14)
Shares, Forfeited	(50,000)	(100,000)
Weighted Average Grant Date Fair Value, Forfeited	$ (0.08)	$ (0.09)
Shares, Nonvested at end of period	2,085,584	2,058,167
Weighted Average Grant Date Fair Value, Nonvested at end of period	$ 0.05	$ 0.07

Shareholders' Equity (Details_9

Shareholders' Equity (Details) - Schedule of Stock Grant Activity - Stock Grants [Member] - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Stock Grant Activity [Line Items]
Shares, Nonvested at beginning of period	1,484,488	1,651,435
Weighted Average Grant Date Fair Value, Nonvested at beginning of period	$ 0.05	$ 0.05
Shares, Granted		160,944
Weighted Average Grant Date Fair Value, Granted		$ 0.09
Shares, Vested	(408,164)	(468,292)
Weighted Average Grant Date Fair Value, Vested	$ (0.05)	$ (0.05)
Shares, Forfeited	(50,000)
Weighted Average Grant Date Fair Value, Forfeited	$ (0.12)
Shares, Nonvested at end of period	1,026,324	1,344,087
Weighted Average Grant Date Fair Value, Nonvested at end of period	$ 0.05	$ 0.06

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)		3 Months Ended
	Mar. 11, 2024	Mar. 31, 2024	Mar. 31, 2023
Commitments and Contingencies [Line Items]
Supplier percentage		91%	95%
Base salary (in Dollars)	$ 150,000

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of Maturities of Operating Lease Liabilities - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Maturities of Operating Lease Liabilities [Line Items]
2024	$ 390,027
2025	467,994
2026	335,634
2027	990
Total lease payments	1,194,645
Less interest	(337,407)
Present value of lease liabilities	$ 857,238	$ 939,419

Segment Reporting (Details)

Segment Reporting (Details)	3 Months Ended
	Mar. 31, 2024 USD ($) segments	Mar. 31, 2023 USD ($)
Segment Reporting [Line Items]
Reportable segments (in segments) | segments	3
Digital Healthcare Division [Member]
Segment Reporting [Line Items]
Intercompany sales	$ 180	$ 180
Medical Distribution Segment [Member]
Segment Reporting [Line Items]
Intercompany sales	$ 0	$ 8,340

Segment Reporting (Details) - S

Segment Reporting (Details) - Schedule of Segment Information - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Segment Reporting Information [Line Items]
Revenue	$ 1,004,232	$ 1,755,154
Operating Expenses
Practice salaries and benefits	583,156	963,657
Other practice operating expenses	482,583	624,247
Cost of product revenue	30,579	32,060
Selling, general and administrative expenses	999,443	1,103,748
Depreciation and amortization	86,509	88,077
Total Operating Expenses	2,182,270	2,811,789
Income (loss) from operations	(1,178,038)	(1,056,635)
Other Segment Information
Loss on extinguishment of debt	96,660	44,763
Amortization of original issue discounts on notes payable	108,265	63,360
Change in fair value of contingent acquisition consideration	(76)	1,706
Interest expense (income)	4,831	44,763
Financing cost		11,381
Identifiable assets	3,890,759	5,825,242	$ 4,280,140
Goodwill		319,958
Patient service revenue, net [Member]
Segment Reporting Information [Line Items]
Revenue	963,621	1,700,281
Subscription, consulting and event revenue [Member]
Segment Reporting Information [Line Items]
Revenue	7,628	16,299
Product and other revenue [Member]
Segment Reporting Information [Line Items]
Revenue	32,983	38,574
Health Services [Member]
Segment Reporting Information [Line Items]
Revenue	963,621	1,700,281
Operating Expenses
Practice salaries and benefits	583,156	963,657
Other practice operating expenses	482,583	624,247
Cost of product revenue
Selling, general and administrative expenses
Depreciation and amortization	85,169	86,672
Total Operating Expenses	1,150,908	1,674,576
Income (loss) from operations	(187,287)	25,705
Other Segment Information
Loss on extinguishment of debt
Amortization of original issue discounts on notes payable	108,265	60,993
Change in fair value of contingent acquisition consideration
Interest expense (income)	3,881
Financing cost		2,812
Identifiable assets	1,635,387	2,204,934	1,812,609
Goodwill		319,958
Health Services [Member] | Patient service revenue, net [Member]
Segment Reporting Information [Line Items]
Revenue	963,621	1,700,281
Health Services [Member] | Subscription, consulting and event revenue [Member]
Segment Reporting Information [Line Items]
Revenue
Health Services [Member] | Product and other revenue [Member]
Segment Reporting Information [Line Items]
Revenue
Digital Healthcare [Member]
Segment Reporting Information [Line Items]
Revenue	7,628	16,299
Operating Expenses
Practice salaries and benefits
Other practice operating expenses
Cost of product revenue
Selling, general and administrative expenses	980,174	1,070,321
Depreciation and amortization	1,340	1,405
Total Operating Expenses	981,514	1,071,726
Income (loss) from operations	(973,886)	(1,055,427)
Other Segment Information
Loss on extinguishment of debt	96,660
Amortization of original issue discounts on notes payable		2,367
Change in fair value of contingent acquisition consideration	(76)	1,706
Interest expense (income)	950	44,763
Financing cost		8,569
Identifiable assets	2,246,600	3,606,105	2,457,849
Goodwill
Digital Healthcare [Member] | Patient service revenue, net [Member]
Segment Reporting Information [Line Items]
Revenue
Digital Healthcare [Member] | Subscription, consulting and event revenue [Member]
Segment Reporting Information [Line Items]
Revenue	7,628	16,299
Digital Healthcare [Member] | Product and other revenue [Member]
Segment Reporting Information [Line Items]
Revenue
Medical Distribution [Member]
Segment Reporting Information [Line Items]
Revenue	32,983	38,574
Operating Expenses
Practice salaries and benefits
Other practice operating expenses
Cost of product revenue	30,579	32,060
Selling, general and administrative expenses	19,269	33,427
Depreciation and amortization
Total Operating Expenses	49,848	65,487
Income (loss) from operations	(16,865)	(26,913)
Other Segment Information
Loss on extinguishment of debt
Amortization of original issue discounts on notes payable
Change in fair value of contingent acquisition consideration
Interest expense (income)
Financing cost
Identifiable assets	8,772	14,203	$ 9,682
Goodwill
Medical Distribution [Member] | Patient service revenue, net [Member]
Segment Reporting Information [Line Items]
Revenue
Medical Distribution [Member] | Subscription, consulting and event revenue [Member]
Segment Reporting Information [Line Items]
Revenue
Medical Distribution [Member] | Product and other revenue [Member]
Segment Reporting Information [Line Items]
Revenue	$ 32,983	$ 38,574

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Fair Value of Financial Instruments [Line Items]
Contingent acquisition consideration payable	$ 76	$ 1,706

Fair Value of Financial Instr_4

Fair Value of Financial Instruments (Details) - Schedule of Fair Value Measurements - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Assets:
Contingent sale consideration receivable	$ 1,663,163	$ 1,663,163
Liabilities:
Contingent acquisition consideration payable	2,113	2,189
Convertible note payable to related party	199,621
Total liabilities	201,734	2,189
Level 1 [Member]
Assets:
Contingent sale consideration receivable
Liabilities:
Contingent acquisition consideration payable
Convertible note payable to related party
Total liabilities
Level 2 [Member]
Assets:
Contingent sale consideration receivable
Liabilities:
Contingent acquisition consideration payable
Convertible note payable to related party
Total liabilities
Level 3 [Member]
Assets:
Contingent sale consideration receivable	1,663,163	1,663,163
Liabilities:
Contingent acquisition consideration payable	2,113	2,189
Convertible note payable to related party	199,621
Total liabilities	$ 201,734	$ 2,189

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Apr. 22, 2024	Apr. 18, 2024	Apr. 12, 2024	Apr. 10, 2024	May 08, 2024	May 06, 2024
Subsequent Events [Line Items]
Principal amount		$ 50,000		$ 150,000
Common stock, share (in Shares)			877,193
Proceeds from the sales			$ 50,000
Warrants to purchase shares issued (in Shares)			438,596
Warrant price (in Dollars per share)			$ 0.16
Principal amount	$ 161,000
Prepaid interest	19,320
Repayments	180,320
Received net proceeds	118,787
Original issue discount	21,000
Fees	5,000
Withholding final payment	16,213
Payments amount	$ 18,032
Conversion right discount percentage	15%
Convertible note payable [Member]
Subsequent Events [Line Items]
Interest rate		12%		12%
Conversion price per share (in Dollars per share)		$ 0.05		$ 0.0577
Dr. Michael Dent [Member]
Subsequent Events [Line Items]
Advance					$ 70,000	$ 100,000